

## Next Science Limited

ACN: 622 382 549

## Appendix 4E

31 December 2024

### Company details

Name of entity: Next Science Limited  
ABN: 47 622 382 549  
Reporting period: For the year ended 31 December 2024  
Previous period: For the year ended 31 December 2023

---

### Results for announcement to the market

				<b>USD \$</b>
Revenues from ordinary activities	up	3%	to	22,816,266
Loss from ordinary activities after tax attributable to the owners of Next Science Limited	down	-35%	to	(10,586,018)
Loss for the year attributable to the owners of Next Science Limited	down	-35%	to	(10,586,018)

#### *Dividends*

No dividend was paid or proposed during the year ended 31 December 2024 (2023: USD \$nil).

Refer to the Operating and Financial Review within the Directors' Report for further commentary on the year's results, financial position and likely developments in future years.

### Net tangible assets

	<b>Reporting period USD Cents</b>	<b>Previous period USD Cents</b>
Net tangible assets/(liabilities) per ordinary security	<u>0.48</u>	<u>3.58</u>

The net tangible asset/(liability) per ordinary security is calculated based on 292,160,234 ordinary shares on issue at 31 December 2024 and 291,695,103 shares that were in existence at 31 December 2023.

### Control gained over entities

Not applicable.

### Loss of control over entities

Not applicable.

**Next Science Limited**

ACN: 622 382 549

**Appendix 4E**  
**31 December 2024**

Other information requiring disclosure to comply with ASX Listing rule 4.3A is contained in, and should be read in conjunction with the Financial Statements, the notes to the Financial Statements and the Directors' Report for the year ended 31 December 2024 attached to this report.

This report is based on the Consolidated Financial Statements and Notes of Next Science Limited which have been audited by KPMG.

**Signed**



---

Aileen Stockburger  
*Chair*

28 February 2024  
Sydney

For personal use only

**Next Science Limited**

ACN 622 382 549

**Annual Report - 31 December 2024**

For personal use only

**Next Science Limited**  
**Contents**  
**31 December 2024**

Directors' report	2
Auditor's independence declaration	22
Consolidated statement of profit or loss and other comprehensive income	23
Consolidated statement of financial position	24
Consolidated statement of changes in equity	25
Consolidated statement of cash flows	27
Notes to the consolidated financial statements	28
Consolidated entity disclosure statement	62
Directors' declaration	63
Independent auditor's report to the members of Next Science Limited	64
Corporate Directory	68

For personal use only

**Next Science Limited**  
**Directors' report**  
**31 December 2024**

The Directors present their report together with the consolidated financial statements of the Group comprising of Next Science Limited (**Next Science/Company**), and the entities it controlled at the end of, or during, the year ended 31 December 2024 (**Group**). All amounts are presented in US dollars (USD) unless otherwise stated.

**Directors**

The Directors of the Company in office during or since the end of the financial year were as follows:

Current

Aileen Stockburger  
Harry Thomas Hall, IV (I.V.)  
Grant Hummel  
Katherine Ostin

Former

Daniel Spira (resigned on 3 May 2024)

**Dividends**

No dividends were paid or declared since the commencement of the year and the Directors do not recommend the declaration of a dividend.

**Operating and financial review**

*Principal activities*

The principal activities of the Group during the course of the year were the research, development and commercialisation of technologies to resolve the issues caused by biofilms and their incumbent bacteria, fungus and viruses and the infections they cause with a focus on human health. The Company is headquartered in Sydney, Australia and has a research and development centre and sales and marketing functions located in Florida, USA.

*Significant changes in the state of affairs*

Revenues grew by 2.9% in 2024 with direct sales of XPERIENCE™ up 99% as a result of increased clinical evidence, extension of the use case from high risk into prophylactic use, and continued expansion of the Group's Purchasing Organisation (GPO) footprint providing a broader access to healthcare sites.

In 2024, the Group focused on implementing a new cost base and a sales transformation to lay the foundations for future growth. The Group restructured the direct sales force team during 1H 2024 with the consolidation of its sales leadership, implementation of a unified field strategy for its XBIO™ product suite, and the restructuring of its Durable Medical Equipment (DME) sales force and go-to-market strategy from a direct sales structure to a model focused on agency representatives who are independent and earn commissions on what they sell resulting in a more variable cost structure for the Group. The remaining direct sales force team will no longer focus on a singular product component (XPERIENCE™, BLASTX™ or DME) but on the entire XBIO™ portfolio. These changes delivered a more scalable sales force and a more variable cost structure with annual cost savings and a significant reduction in cash burn.

On 17 July 2024, the Group announced that it had entered into a facility agreement with TIGA Trading Pty Ltd (a company associated with Thorney Investment Group) (Thorney) to provide a US\$5 million unsecured loan facility with a maturity date of 17 July 2026 (Facility). The Facility provides a buffer against unexpected financial challenges and flexibility to respond should investment opportunities arise. Interest is payable at 12% per annum on amounts drawn under the Facility and accrued interest is payable on the earlier of the Facility termination date and the date the principal outstanding is repaid in full. The total amount drawn down on the Facility as at 31 December 2024 amounted to US\$2 million. In conjunction with the execution of the Facility Agreement, the parties signed an option deed under which Next Science agreed to issue to Thorney 5 million unquoted options over ordinary shares in the Company at an exercise price of A\$0.42 and with a three-year expiry. The 5 million options were issued on 17 July 2024.

**Operating and financial review (continued)**

*Significant changes in the state of affairs (continued)*

In October 2024, the Company announced the publication of the findings of a retrospective 1,295-patient study by leading orthopaedic surgeon Dr. Bashyal. The study found XPERIENCE™ to be efficacious in preventing periprosthetic joint infection (PJI) in patients undergoing primary total knee (TKA) and hip (THA) arthroplasties (joint replacement).

In the opinion of the Directors, other than the events previously stated, there were no further significant changes in the state of affairs of the Group that occurred during the year.

*Shareholder returns*

	<b>2024</b>	<b>2023</b>
Revenue	<b>\$22,816,266</b>	<b>\$22,179,327</b>
Loss attributable to owners of the company	<b>(\$10,586,018)</b>	<b>(\$16,270,814)</b>
Basic earnings per share (EPS) (cents)	<b>(\$3.63)</b>	<b>(\$6.95)</b>
Share price as at 31 Dec (A\$)	<b>AUD\$0.120</b>	<b>AUD\$0.340</b>
Return on capital employed	<b>(171.9%)</b>	<b>(113.4%)</b>

*Review of operations*

The loss for the Group for the financial year to 31 December 2024 after providing for income tax amounted to \$10,586,018 (2023: \$16,270,814).

Revenue increased by 2.9% for the period increasing from \$22,179,327 in the prior corresponding period to \$22,816,266. The increase in sales included continued growth in the Surgical business with direct sales of XPERIENCE™ offsetting a sales decline in the Durable Medical Equipment (DME) channel due to the transition to a predominantly agency salesforce.

Gross profit for FY24 was \$18,443,406 compared to \$16,234,576 in the prior corresponding period. Gross margin as a percent of sales was 81% compared with 73% in the prior corresponding period.

Selling and distribution expenses were \$16,067,483, a decrease of \$4,097,852 compared with \$20,165,335 in the prior corresponding period. The decrease in spend in 2024 mainly relates to the sales force restructuring with a significant decrease in the size of the direct sales force and transition to a predominantly agency salesforce resulting in a more variable cost structure for the Group. Agency representatives (1099s) are independent t and earn commissions on what they sell.

Research and development expenses were \$5,950,269, a decrease of \$535,255 compared with \$6,485,524 in the prior corresponding period. Whilst there was continued spend on research and development projects and clinical studies there were less costs incurred.

Administration expenses were \$6,752,235, an increase of \$1,141,776 compared with \$5,610,459 in the prior corresponding period. The increase mainly relates to the issue of performance rights and options as part of the Group's Long Term Incentive Plan and legal costs associated with litigation against several former employees for breach of post-employment restraints.

Cash and cash equivalents at 31 December 2024 amounted to \$1,673,917 compared to \$9,238,697 at 31 December 2023. Term deposits at 31 December 2024 amounted to \$Nil compared to \$37,823 at 31 December 2023.

The Directors have considered uncertainties arising from geo-political conflicts, the interest and inflation outlook and climate-related risks and do not expect any significant impact on the Group arising from these matters.

## **Operating and financial review (continued)**

### *Inherent risks of Investments in Health Care Companies*

There are many inherent risks associated with the development of medical devices to a marketable stage. The sale and distribution of some of Next Science's products is subject to obtaining and maintaining regulatory approvals, and other clearances from the relevant regulatory body in the jurisdiction, such as the Food and Drug Administration (FDA) in the USA and the Therapeutic Goods Administration (TGA) in Australia. Next Science's success depends on its ability to develop and market products that are recognised and accepted as reliable, efficacious and cost effective. Market acceptance depends on many factors including clinical evidence demonstrating the clinical and cost benefit outcome of the products. Clinical evidence may be conducted by third parties and as such the Company is partially reliant on the accuracy and efficacy of the reports produced by those third parties. There is no guarantee that adoption of the Company's existing products and future products will be sufficient to meet the Company's sales objectives.

Other risks include patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary regulatory authority approvals and difficulties caused by rapid advancements in technology.

### **Likely developments and expected results of operations**

Further information about likely developments in the operations of the Group and the expected results of those operations in future financial years has not been included in this report because disclosure of the information would be likely to result in unreasonable prejudice to the Group.

### **Matters subsequent to the end of the financial year**

On 8 January 2025, Next Science advised that it was involved in litigation against several former employees for breach of post-employment restraints (Non-Compete Action) and that one of the former employees had filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging mismanagement and breaches of fiduciary duties. The Company's Board of Directors is concerned that the Complaint has not been brought in good faith due to the fact that the former employee has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged.

In February 2025, the Group was issued with a Warning Letter relating to the US Food and Drug Administration (FDA) inspection of the Company's Jacksonville, Florida facility during August and September 2024. Following the FDA's inspection, the FDA provided the Company with a list of observations, via a Form FDA-483. The Group implemented corrective actions addressing the FDA's observations. The Warning Letter notes the corrective actions undertaken as well as ongoing corrective actions and states that a follow-up inspection is needed to evaluate the implementation and effectiveness of the Company's corrective actions.

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event, other than those matters detailed above, of a material and unusual nature likely, in the opinion of the directors of the Company, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group, in future financial years.

### **Environmental regulation**

The Group's operations are not subject to significant environment regulations under either Commonwealth or State legislation. The Board believes that the Group has adequate systems in place for the management of environmental requirements.

### **Government regulation**

The Group is subject to varying degrees of governmental regulation in the countries in which its operations are conducted, and the general trend is towards increasingly stringent regulation. In the U.S., the drug, device, diagnostics and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labelling and safety reporting. The exercise of broad regulatory powers available to the U.S. Food and Drug Administration (the "FDA") can result in increases in the amounts of testing and documentation required for FDA clearance of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.

**Government regulation (continued)**

The Jacksonville based subsidiary, Next Science LLC, is licensed and accredited by US Medicare, as a Durable Medical Equipment (DME) provider based in the State of Florida, USA. Such licensing and accreditation, brings with it additional regulatory and compliance obligations. Being accredited as a DME business, Next Science must comply with the U.S Health Insurance Portability and Accountability Act (HIPAA) which requires companies that deal with protected health information to have physical, network, and process security measures in place and follow them. Next Science needs to ensure that it maintains its HIPAA compliance in order to continue to be accredited as a DME entity.

The Group relies on global supply chains, and production and distribution processes that are complex and are subject to lengthy regulatory approval processes and ongoing regulatory requirements which can affect sourcing, supply and pricing of materials used in the Group's products.

**Information on Directors**

---

Name:	Aileen Stockburger
Title:	Chair and Independent Non-Executive Director
Special responsibilities:	Member, Audit and Risk Committee Member, People, Culture and Remuneration Committee
Qualifications:	Bachelor of Science and MBA, The Wharton School, University of Pennsylvania, Graduate of the Australian Institute of Company Directors, Certified Public Accountant (CPA – USA).
Experience and expertise:	Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately \$21 billion, Johnson & Johnson's largest medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US\$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena.
Other listed company directorships in last three years:	Non-Executive Director, Microbot Medical Inc. (NASDAQ: MBOT).

---

For personal use only



**Information on Directors (continued)**

Name:	Harry Thomas Hall, IV (I.V. Hall)
Title:	Managing Director and Chief Executive Officer
Special responsibilities:	None
Qualifications:	Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering, Clemson University  MBA, Pennsylvania State University  Advanced Management Program, Harvard Business School
Experience and expertise:	I.V. has more than 28 years' experience in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. Prior to joining Next Science, I.V. was a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE: JNJ), and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. I.V. joined DePuy Synthes in 1997 where he held senior roles including: Global Vice President – MedTech R&D and Worldwide President – Trauma, Extremities, Craniomaxillofacial & Animal Health. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V. was responsible for a global portfolio and execution strategy for a US\$3.2bn platform including upstream marketing and commercial planning in the Global Orthopaedic Unit of DePuy Synthes. In addition to managing over 1,100 staff across sales, marketing and R&D, I.V. created and sustained personal relationships with well over one hundred key opinion leaders worldwide.
Other listed company directorships in last three years:	None

Name:	Grant Hummel
Title:	Independent Non-Executive Director
Special responsibilities:	Chair, People Culture and Remuneration Committee
Qualifications:	Bachelor of Science with an honours degree in molecular genetics and Bachelor of Laws (Honours), University of Tasmania Graduate Diploma of Applied Finance and Investment, FINSIA (now Kaplan)
Experience and expertise:	Grant was part of Next Science's ASX listing deal team in 2019. He has been a partner of a major Australian law firm, for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients.
Other listed company directorships in last three years:	Non-Executive Director of GLG Corp Ltd (ASX:GLE)

For personal use only

**Information on Directors (continued)**

---

Name:	Katherine Ostin
Title:	Independent Non-Executive Director
Special responsibilities:	Chair, Audit and Risk Committee
Qualifications:	Bachelor of Commerce (Accounting and Finance), University of New South Wales Fellow of the Financial Services Institute of Australasia Graduate, Australian Institute of Company Directors
Experience and expertise:	Kathy is an experienced non-executive director and audit and risk committee chair. Kathy was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in aged care and healthcare sectors, having established and led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK.
Other listed company directorships in last three years:	Non-Executive Director of 3P Learning Limited (ASX:3PL) since August 2021 Non-Executive Director of Dusk Group Limited (ASX:DSK) since September 2020 Non-Executive Director of Capral Limited (ASX:CAA) since June 2020 Non-Executive Director of Elanor Investors Group Limited (ASX: ENN) and Elanor Commercial Property Fund (ASX: ECF) since January 2024 Non-Executive Director of Healius Limited (ASX:HLS) since December 2024

---

Name:	Daniel Spira (retired 3 May 2024)
Title:	Independent Non-Executive Director
Special responsibilities:	Chair, People, Culture and Remuneration Committee
Qualifications:	Bachelor of Commerce, University of New South Wales
Experience and expertise:	Dan is the CEO of iNova Pharmaceuticals (since 2017), a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously, he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region.  Prior to that, Dan spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.
Other listed company directorships in last three years:	None

---

For personal use only

**Next Science Limited**  
**Directors' report**  
**31 December 2024**

**Company Secretary**

Gillian Nairn, BA/LLB, LLM, FGIA, was appointed Company Secretary on 21 June 2018. Gillian is an experienced corporate governance professional with more than 20 years legal and governance experience gained in private practice and in various in-house and consulting company secretarial roles, predominantly with listed entities.

**Meetings of directors**

The number of meetings held and attended by each of the Directors of the Company during the year ended 31 December 2024 were as follows:

Name of director	Board meetings		People, Culture & Remuneration Committee		Audit and Risk Committee	
	A <sup>1</sup>	B <sup>2</sup>	A	B	A	B
Aileen Stockburger	21	20	3	3	6	6
Harry Thomas Hall, IV	21	20	-	-	-	-
Grant Hummel	21	21	3	3	6	6
Katherine Ostin	21	21	1	1	6	6
Daniel Spira <sup>3</sup>	7	6	2	2	-	-

<sup>1</sup>A - Number of meetings held

<sup>2</sup>B - Number of meetings attended by the Director during the time the Director was a member of the Board or Committee

<sup>3</sup>Retired on 3 May 2024

**Directors' interests**

The relevant interest of each Director in shares, options and rights over such instruments issued by the Group, as notified by the Directors to the ASX in accordance with section 205G(1) of the Corporations Act 2001 at the date of this report is as follows:

Director	Fully paid ordinary shares		Share options or rights	
	Number		Number	
Aileen Stockburger	569,638		-	-
Grant Hummel	387,694		-	-
Harry Thomas Hall, IV (I.V. Hall)*	665,131		930,262	Sign-on Rights
			1,814,394	Performance Rights
			3,361,855	Options
Katherine Ostin	-		-	-
<b>Total</b>	<b>1,622,463</b>		<b>6,106,511</b>	

\***Note:** I.V. Hall has a contractual right to a sign-on grant of rights and has been issued further rights and options under the LTI Plan. Refer page 14 for further details.

**Shares under option and rights**

As at 31 December 2024, there are 26,150,521 options and 13,385,230 rights over ordinary shares on issue (2023: 6,349,967 options and 2,017,151 rights), representing 13.5% (2023: 2.87%) of the Company's total share capital, granted to the employees and Directors of the Company.

**Indemnity and insurance of officers**

The Group has indemnified the Directors and executives of the Group for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Group has paid a premium in respect of a contract to insure the Directors and executives of the Company against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

### **Indemnity and insurance of auditor**

The Company and the Group have not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

### **Proceedings on behalf of the company**

No person has applied to a court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

A former employee of the Company has filed a derivative lawsuit in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, without seeking leave to do so, as required under section 237. The complaint makes various allegations against alleged officers and directors of Next Science Limited and Next Science, LLC. The Company has filed a motion to dismiss the complaint on grounds including that the plaintiff lacks standing to bring his claims due to his failure to satisfy the requirements imposed upon derivative plaintiffs by Australian law.

### **Non-audit services**

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 35 to the financial statements.

The Directors are satisfied that the provision of non-audit services by the auditor during the financial year is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*.

The Directors are of the opinion that the services as disclosed in note 35 to the financial statements do not compromise the external auditor's independence requirements under the *Corporations Act 2001* for the following reasons:

- All non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- The external auditor has declared to the Directors that to the best of the individual auditor's knowledge and belief, there have been no contraventions of the auditor independence requirements of the Corporations Act and no contraventions of any applicable code of professional conduct in relation to the audit for the year ended 31 December 2024.
- The non-audit services provided do not undermine the general principles relating to auditor independence as set out in APES 110 *Code of Ethics for Professional Accountants* (including *Independence Standards*), as they did not involve reviewing or auditing the auditor's own work, acting in a management or decision making capacity for the Company, acting as an advocate for the Company or jointly sharing risks and rewards.

### **Officers of the Company who are former partners of KPMG**

No officer of the Company was an audit partner of KPMG, being the auditors during the financial year, at a time when the audit firm undertook an audit of the Company.

### **Auditor's independence declaration**

The auditor's independence declaration is set out on page 22 and forms part of the Directors' Report for the financial year ended 31 December 2024.

### **Auditor**

KPMG continues in office in accordance with section 327 of the *Corporations Act 2001*.

### **Remuneration Report (audited)**

This Remuneration Report forms part of the Directors' Report for the year ended 31 December 2024. This Report outlines the details of the remuneration arrangements for the key management personnel of the Group, including remuneration strategy, framework and practices, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

For the purposes of this Report, key management personnel (**KMP**) are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including any director of the Company (non-executive or executive).

The information in this Remuneration Report is set out under the following headings:

- Key management personnel
- Remuneration governance
- Service agreements and remuneration policy
- Non-Executive Directors' remuneration
- Employee incentive arrangements and link between performance and reward
- Share option plans and performance rights over equity instruments
- KMP Remuneration
- KMP Equity Holdings

#### **Key management personnel**

The KMP of the Group during the financial year and the positions held are summarised below:

##### *Non-Executive Directors*

Aileen Stockburger, Chair

Grant Hummel

Katherine Ostin

Daniel Spira (resigned on 3 May 2024)

##### *Managing Director and CEO*

Harry Thomas Hall, IV (I.V.)

##### *Other KMP*

Marc Zimmerman

(Chief Financial Officer)

Matthew Myntti

(Chief Technology Officer)

Jon Swanson

(Chief Operating Officer)

#### **Remuneration governance**

The People, Culture and Remuneration-Committee comprises the following members:

- Grant Hummel (Chair – appointed on 4 May 2024)
- Aileen Stockburger
- Katherine Ostin (appointed on 28 August 2024)
- Daniel Spira (resigned on 3 May 2004)

The role and responsibilities, composition, structure and membership requirements of the People, Culture and Remuneration Committee are documented in the People, Culture and Remuneration Committee Charter available at [www.nextscience.com/corp-governance](http://www.nextscience.com/corp-governance).

The People, Culture and Remuneration Charter provides that the Committee should comprise of only non-executive Directors, at least three members, the majority of whom are independent Directors and a chair appointed by the Board who is an independent Director and is not Chair of the Board.

The Chair of the Committee should be an independent Director who is not Chair of the Board.

The Charter requires the Committee to meet at least twice each year.

All of the current members of the People, Culture and Remuneration Committee have been assessed by the Board as being independent Non-Executive Directors and the Chair of the Committee is not Chair of the Board.

**Service agreements and remuneration policy**

Executives are employed under executive employment agreements with the Group.

In determining remuneration, the Group considers:

- industry based remuneration benchmarking (Australia and USA);
- market developments affecting remuneration practices;
- the remuneration expectations of an executive whom the Company wants to employ;
- future outlook for the Group and market generally;
- the Company's performance over a performance period; and
- the link between remuneration and the successful implementation of the Company's strategy and achievement of strategic objectives.

Executive incentives comprise fixed and variable elements linked to Company and individual performance as detailed in this Report.

*Employment agreements*

---

Name: Harry Thomas Hall, IV (I.V. Hall)  
Title: Managing Director and Chief Executive Officer (CEO)  
Details: Ongoing service agreement.

If the Company terminates I.V.'s employment without Cause or I.V. resigns other than for Good Reason, 90 days' notice must be provided.

If I.V. resigns for Good Reason, the Company must continue to pay I.V. for 6 months from the termination date; up to 6 months of COBRA<sup>1</sup> reimbursement; pro rata STI for current year payable in a single cash lump sum on the date the STI otherwise would have been paid; earned and unpaid STI for the previous year; and accelerated vesting of outstanding service-based equity grants and continued eligibility for vesting of performance-based equity grants (in each case on a pro rata basis).

The Company can terminate immediately for Cause.

I.V. is entitled to participate in the Company's short and long-term incentive plans.

I.V.'s services agreement contains standard provisions regarding duties, leave entitlements, confidentiality, intellectual property, non-competition and non-solicitation restrictions.

---

<sup>1</sup>COBRA is a US law that allows former employees to elect to remain as participants in their former employer's group health insurance plan for a limited period of time after termination of employment

For personal use only

**Service agreements and remuneration policy (continued)**

*Employment agreements (continued)*

---

Name: Marc Zimmerman  
Title: Chief Financial Officer (CFO)  
Details: Ongoing service agreement.

Marc's employment may be terminated by either party at any time and for any reason on 60 days' notice. If Marc resigns, the Company may unilaterally accelerate the date of termination.

Marc is entitled to participate in the Company's short and long-term incentive plans.

Marc's services agreement contains standard provisions regarding duties, leave entitlements, confidentiality, intellectual property, and non-competition and non-solicitation restrictions.

---

Name: Dr Matthew Myntti  
Title: Chief Technology Officer (CTO)  
Detail: Ongoing employment agreement to be reviewed annually by the Company.

The Company or employee may terminate the service agreement by giving 90 days written notice.

The Company may terminate immediately for Cause as defined in the agreement.

Matthew is entitled to participate in the Company's short term and long-term incentive plans.

---

Name: Jon Swanson  
Title: Chief Operating Officer (COO)  
Details: Jon was appointed as Chief Strategy Officer on 2 January 2025. Prior to that date, Jon performed the role of Chief Operating Officer (COO).

Ongoing employment agreement to be reviewed annually by the Company.

The Company or employee may terminate the service agreement by giving 90 days written notice.

The Company may terminate immediately for Cause as defined in the agreement.

Jon is entitled to participate in the Company's short term and long-term incentive plans.

---

For personal use only

## **Non-Executive Directors' Remuneration**

Each of the Non-Executive Directors has entered into appointment letters with Next Science confirming the terms of their appointment and their roles and responsibilities.

Under the Constitution, the Board has authority to decide the amount paid to each Non-Executive Director as remuneration for their services as a Director. However, the Constitution and the ASX Listing Rules stipulate that the total amount of fees paid to Non-Executive Directors (excluding any special exertion fees) must not exceed the amount approved by the Company's shareholders. This amount has been fixed initially in the Company's Constitution at A\$750,000 per annum and may only be varied by ordinary resolution in general meeting.

The annual fee for Non-Executive Directors is AUD\$90,000 per annum (inclusive of superannuation) and for the Chair is USD\$175,000 per annum (inclusive of superannuation). The Chair's fees reflect the additional responsibilities of the role. An additional fee of AUD\$10,000 per annum is paid for performing the role of Chair of the Audit and Risk Committee or the People, Culture and Remuneration Committee. The Company paid special exertion fees to Aileen Stockburger during 2024 and 2023. Effective from 1 January 2024, the exertion fee paid has been USD\$1,000 per week. The exertion fees have been in consideration for assisting the Board in ensuring the Company's activities in the US receive appropriate Board oversight and support.

## **Employee incentive arrangements and link between performance and reward**

### *Short Term Incentive (STI) Plan for Executives*

The CEO, CFO, CTO, Chief Operating Officer (COO) and Chief Strategy Officer (CSO) are eligible to participate in the Company's short-term incentive plan (**STI Plan**). As at the date of this report, the Company has not appointed a COO.

The STI Plan year is defined as 1 January until 31 December in a given year.

Participants in the STI Plan, must be employed with the Company, or a wholly owned subsidiary of the Company, for at least six months during the Plan year. Participants who resign or are terminated before the end of a Plan year are not eligible for any payments under the Plan unless the Board determines otherwise, in its sole discretion.

The objectives of the STI Plan are to:

- reward executives for their contribution to ensuring that Next Science achieves its annual goals and objectives;
- enhance Next Science's opportunity to attract, motivate and retain high calibre and high performing executives; and
- link part of executive remuneration directly to the achievement of Company and individual key performance objectives.

The making of any payment under the STI Plan is subject to the achievement of revenue and EBITDA performance gateway hurdles and an individual performance rating of at least 'meets expectations'.

The maximum STI opportunity is 100% of Total Fixed Remuneration (TFR) for the CEO and 80% of TFR for the other executive participants. To receive the maximum STI opportunity, the Company must achieve above 100% of Company performance targets and individual performance must be assessed as being at the top level of 'extraordinary'.

As a number of the members of the executive team already have significant security holdings in Next Science, any payments under the STI Plan are paid in cash to ensure that the STI opportunities operate as true incentives.

No STI payments were made in respect of the financial year ended 31 December 2024 (2023: Nil) as the gateway revenue and EBITDA targets were not met.

### *Equity Plan for eligible persons*

At the time of the Company's initial public offering (IPO) in April 2019, the Board of the Company established an equity incentive plan to facilitate the grant of equity to eligible persons to align their interests with shareholders through the sharing of a personal interest in the future growth and development of the Company (**NXS Employee Equity Plan**).

In May 2023, Next Science issued 700,000 options with an exercise price of A\$0.68 and expiry date of 1 May 2028 to employees under the NXS Employee Equity Plan. The only equity issued to employees in 2024 was issued under the Company's Long Term Incentive Plan, as detailed below.

### *Long-Term Incentive (LTI) Plan*

At the time of the Company's IPO, the Company also established a long-term incentive plan (**LTI Plan**) under which the Company could issue equity incentives to eligible executives of the Company.



### **Employee incentive arrangements and link between performance and reward (continued)**

During the financial year ended 31 December 2023, the Board undertook a review of the Company's approach to long term incentives, assisted by external remuneration consultants, with the key objectives of the review including ensuring that the LTI Plan was appropriate for the size of the Company and its stage of development, the LTI Plan was aligned to the Company's strategy and commercialisation goals and the LTI Plan was simple to understand and valuable to all participants.

This review led to the Board revising the Company's LTI Plan in 2023 with a key change being the form of equity offered under the plan. Whereas previously the LTI Plan offered participants performance rights only, the LTI Plan now offers participants an equal split of performance rights and options ie. 50% performance rights and 50% options.

The eligible participants in the 2024 LTI Plan were the CEO, CFO, CTO, COO and Senior Vice-President, Sales, VP Product Development, VP Clinical & Regulatory Affairs, and VP Operations.

On 24 July 2023, 7,366,333 options and 2,629,928 Performance Rights were issued under the Company's 2023 LTI Plan to members of the executive team who had been with the Company for more than 12 months. Similarly, on 3 May 2024, 3,361,855 options and 1,814,394 Performance Rights were issued; and on 16 September 2024, 16,788,699 options and 8,623,423 Performance Rights were issued under the Company's 2024 LTI Plan to members of the executive team who had been with the Company for more than 12 months.

The grant of equity under the NXS Employee Equity Plan or the LTI Plan is governed by the Next Science Employee Equity Plan Rules.

The number of Performance Rights granted under the LTI Plan, as amended, is based on the volume weighted average price (VWAP) of shares in the Company during the 30 days to 30 June in the relevant plan year.

The vesting of Performance Rights issued under the 2024 LTI Plan is dependent on satisfaction of vesting conditions relating to relative total shareholder return (Relative TSR) and continued employment during a three-year performance period. Relative TSR compares the Company's TSR performance against the TSR of a bespoke peer group comprising companies in the ASX 101-500 within the Health Care Global Industry Classification Standard (GICS) sector.

If Relative TSR performance is less than the 50<sup>th</sup> percentile, no performance right will vest. At the 50<sup>th</sup> percentile 50% of the performance rights vest and at the 75<sup>th</sup> percentile, 100% of the performance rights vest. In-between the 50<sup>th</sup> and 75<sup>th</sup> percentiles, vesting occurs on a pro rata basis.

Subject to vesting conditions being satisfied, performance rights automatically convert to shares, on a one-for one basis, three years after the date on which they are granted. If vesting conditions have not been satisfied, the performance rights will automatically lapse. Participants must be employed by the Company or a wholly owned subsidiary at the date of vesting.

During the financial year ended 31 December 2024, 10,437,817 Performance Rights were issued under the Company's LTI Plan (2023: 2,629,928) and 1,395,393 Sign-on Rights were issued to the CEO.

The CEO was entitled to an initial sign-on grant of performance rights equivalent in value to US\$500,000, vesting in equal tranches annually over a three-year period subject to continuous employment. The grant of the sign-on rights was approved by shareholders at the Company's 2024 Annual General Meeting. The first tranche of sign-on rights vested on 10 July 2024. Provided the CEO meets the continuous employment requirement, tranche 2 of the sign on rights will vest on 10 July 2025 and tranche 3 will vest on 10 July 2026. As at 31 December 2024, and at the date of this report, the CEO holds 930,262 sign-on rights.

Options issued under the 2024 LTI Plan were issued in two equal tranches. The vesting of one tranche is subject to continued employment on the relevant vesting date and the vesting of the second tranche is dependent on satisfaction of a share price hurdle and continued employment on the relevant vesting date.

The Options are only exercisable during a two-year period commencing on the third anniversary of the grant date of the options and ending on the fifth anniversary of the grant date. Any Options that have not been exercised by the end of this exercise period lapse.

If a participant resigns or is terminated for cause (including due to a material breach of their obligations to Next Science), all vested but unexercised Options immediately lapse on cessation. If a participant ceases employment for any other reason, any vested but unexercised Options that they hold may be exercised within a period of 60 calendar days (or such other period determined by the Board) from the start of the exercise period applicable to the options, after which time they will lapse.

During the year ended 31 December 2024, 20,150,554 options were issued under the Company's LTI Plan). (2023: 7,366,333).

**Employee incentive arrangements and link between performance and reward (continued)**

No rights or options lapsed on 31 December 2024 due to an executive's employment ending.

Details of the options over ordinary shares issued under the LTI Plan which were held by KMP as at 31 December 2024 are set out below:

KMP	Grant date	Expiry date	Vesting date	Fair value at grant date (USD)	Exercise price (AUD)	Exercise price (USD)
<i>Executive Director</i>						
Harry Thomas Hall, IV (I.V.)	3 May 2024	3 May 2029	(i)	225,000	0.38	0.25
	3 May 2024	3 May 2029	(ii)	199,071	0.38	0.25
<i>Non-Executive Directors</i>						
Aileen Stockburger	-	-	-	-	-	-
Grant Hummel	-	-	-	-	-	-
Katherine Ostin	-	-	-	-	-	-
<i>Other KMP</i>						
Marc Zimmerman	16 Sep 2024	16 Sep 2029	(iii)	118,125	0.22	0.15
	16 Sep 2024	16 Sep 2029	(iv)	58,028	0.22	0.15
Jon Swanson	24 Jul 2023	24 July 2028	(v)	202,584	0.72	0.49
	16 Sep 2024	16 Sep 2029	(iii)	101,292	0.22	0.15
Matthew Myntti	16 Sep 2024	16 Sep 2029	(iv)	49,759	0.22	0.15
	24 Jul 2023	24 July 2028	(v)	275,625	0.72	0.49
	16 Sep 2024	16 Sep 2029	(iii)	137,813	0.22	0.15
	16 Sep 2024	16 Sep 2029	(iv)	67,699	0.22	0.15

(i) The Vesting date of the options is the third anniversary from the grant date, 3 May 2024. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date being 3 May 2027 to 3 May 2029 and subject to the employee remaining employed by the Group.

(ii) The Vesting date of the options is third anniversary from the grant date, 3 May 2024. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date being 3 May 2027 to 3 May 2029 provided the employee remained employed by the Group and the share price reaches AUD\$1.00.

(iii) The Vesting date of the options is the third anniversary from the grant date, 16 September 2024. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date being 16 September 2027 to 16 September 2029 and subject to the employee remaining employed by the Group.

(iv) The Vesting date of the options is the third anniversary from the grant date, 16 September 2024. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date being 16 September 2027 to 16 September 2029 and subject to the employee remaining employed by the Group and the share price reaches AUD\$1.00.

(v) The Vesting date of the options can be any date between the grant date of 24 July 2023, and 3 years from the grant date. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date being 24 July 2026 to 24 July 2028.

For personal use only

**Employee incentive arrangements and link between performance and reward (continued)**

Details of the rights issued under the LTI Plan which were held by KMP as at 31 December 2024 are set out below:

	Number of rights granted	Grant date	Expiry date*	Vesting condition	Fair value at grant date** (USD)
<i>Executive Director</i>					
Harry Thomas Hall, IV (I.V.)	930,262	3 May 2024	N/A	(i)	201,966
	1,814,394	3 May 2024	N/A	(ii)	325,211
<i>Other KMP</i>					
Marc Zimmerman	1,557,039	16 Sep 2024	N/A	(iii)	156,502
Jon Swanson	551,691	24 Jul 2023	N/A	(iv)	157,178
	1,335,159	16 Sep 2024	N/A	(iii)	134,200
Matthew Myntti	750,601	24 Jul 2023	N/A	(iv)	213,848
	1,816,546	16 Sep 2024	N/A	(iii)	182,586

No expiry date applies to the Rights other than that any Rights for which the Vesting Conditions have not been met shall be forfeited.

\* The maximum amount to yet vest under the LTI Plan is \$867,038 as at 31 December 2024.

(i) 930,262 Sign-on Rights vesting in equal tranches annually subject to continued employment (Tranche 2 vests on 10 July 2025 and Tranche 3 vests 10 July 2026).

(ii) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 3 May 2024, to 3 May 2027.

(iii) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 16 September 2024, to 16 September 2027.

(iv) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 24 July 2023, to 24 July 2026.

For personal use only

**Next Science Limited**  
**Directors' report**  
**31 December 2024**

**Options and rights over equity instruments**

The movement for the year ended 31 December 2024, in the number of rights and options over ordinary shares in Next Science Limited held, directly, indirectly or beneficially, by each KMP, including their related parties was as follows:

KMP	Instrument	Balance as at 1 Jan 2024 No.	Granted No.	Exercised No.	Lapsed No.	Balance as at 31 Dec 2024 No.	Vested during the year	Vested and exercisable No.	Un-vested No.
<b>Options and Rights</b>									
<i>Executive Director</i>									
Harry Thomas Hall, IV (I.V.)	Options	-	3,361,855	-	-	3,361,855	-	-	3,361,855
	Rights	-	3,209,787	(465,131)	-	2,744,656	-	-	-
<i>Non-Executive Directors</i>									
Aileen Stockburger	-	-	-	-	-	-	-	-	-
Grant Hummel	-	-	-	-	-	-	-	-	-
Katherine Ostin	-	-	-	-	-	-	-	-	-
<i>Other KMP</i>									
Marc Zimmerman	Options	-	3,031,355	-	-	3,031,355	-	-	3,031,355
	Rights	-	1,557,039	-	-	1,557,039	-	-	-
Jon Swanson	Options	1,545,267	2,599,383	-	-	4,144,650	-	-	4,144,650
	Rights	551,691	1,335,159	-	-	1,886,850	-	-	-
Matthew Myntti	Options	2,102,408	3,536,581	-	-	5,638,989	-	-	5,638,989
	Rights	750,601	1,816,546	-	-	2,567,147	-	-	-

**Exercise of options granted as compensation**

During the reporting period, there were no shares issued upon the exercise of options previously granted as compensation, to KMP.

For personal use only

**Details of equity incentives affecting current and future remuneration**

KMP	Instrument	Number	Grant date	Expiry date	% vested	Financial years in which grant vests
<i>Executive Director</i>						
Harry Thomas Hall, IV (I.V.)	Options	3,361,855	3 May 2024	3 May 2029	-	(i)
	Rights	1,814,394	3 May 2024	-	-	(ii)
	Sign-on Rights	465,131	3 May 2024	10 Jul 2025	-	(iii)
	Sign-on Rights	465,131	3 May 2024	10 Jul 2026	-	(iii)
<i>Non-Executive Directors</i>						
Aileen Stockburger	-	-	-	-	-	-
Grant Hummel	-	-	-	-	-	-
Katherine Ostin	-	-	-	-	-	-
<i>Other KMP</i>						
Marc Zimmerman	Options	3,031,355	16 Sep 2024	16 Sep 2029	-	(iv)
	Rights	1,557,039	16 Sep 2024	-	-	(v)
Jon Swanson	Options	1,545,267	24 Jul 2023	24 Jul 2028	-	(vi)
	Options	2,599,383	16 Sep 2024	16 Sep 2029	-	(vii)
	Rights	551,691	24 Jul 2023	-	-	(viii)
	Rights	1,335,159	16 Sep 2024	-	-	(v)
Matthew Myntti	Options	2,102,408	24 Jul 2023	24 Jul 2028	-	(vi)
	Options	3,536,581	16 Sep 2024	16 Sep 2029	-	(vii)
	Rights	750,601	24 Jul 2023	-	-	(viii)
	Rights	1,816,546	16 Sep 2024	-	-	(v)

(i) The Vesting date of the options is the third anniversary from the grant date, 3 May 2024. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date being 3 May 2027 to 3 May 2029 and subject to the employee remaining employed by the Group.

(ii) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 3 May 2024, to 3 May 2027.

(iii) Sign-on Rights vest in equal tranches annually subject to continued employment (Tranche 2 vests on 10 July 2025 and Tranche 3 vests 10 July 2026).

(iv) The Vesting date of the options is third anniversary from the grant date, 16 September 2024. However, the options are only exercisable during the two year period starting on the third anniversary of the grant date.

(v) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 16 September 2024, to 16 September 2027.

(vi) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 24 July 2023, to 24 July 2026.

(vii) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 24 July 2023, to 24 July 2026 being 16 September 2027 to 17 September 2029 and subject to the employee remaining employed by the Group.

(viii) Vesting conditions include continued employment and Relative Total Shareholder Return over the Performance Period from grant date, 24 July 2023, to 24 July 2026.

For personal use only

**Next Science Limited**  
**Directors' report**  
**31 December 2024**

**KMP Remuneration**

The table below details the remuneration of the KMP based on the remuneration policies discussed in this report for the year ended 31 December 2024.

**Year ended 31 December 2024**

KMP (USD)	Cash salary and fees	Other cash benefits (i)	Long service leave	Super- annuation	Share- based payments (options and rights) (ii)	Total	Performance Related (iii)
	\$	\$	\$	\$	\$	\$	%
<i>Executive Directors</i>							
Harry Thomas Hall, IV (I.V.)	450,000	44,918	-	-	357,242	852,160	41.9
<i>Non-Executive Directors</i>							
Aileen Stockburger	227,604	-	-	-	-	227,604	-
Grant Hummel	57,265	-	-	6,447	-	63,712	-
Katherine Ostin	65,438	-	-	545	-	65,983	-
Daniel Spira (Terminated on 3 May 2024)	22,711	-	-	-	-	22,711	-
<i>Other KMP</i>							
Marc Zimmerman	319,998	-	-	-	38,236	358,234	10.7
Matthew Myntti	373,331	7,820	-	-	200,111	581,262	34.4
Jon Swanson	301,837	200	-	-	147,081	449,118	32.7
	<b>1,818,184</b>	<b>52,938</b>	-	<b>6,992</b>	<b>742,670</b>	<b>2,620,784</b>	<b>28.0</b>

(i) Other cash benefits for I.V., Matthew Myntti and Jon Swanson includes motor vehicle allowance and/or other minor benefits.

(ii) Share based payments were issued under the Company's Long-Term Incentive Plan in the form of performance rights and share options. Refer to pages 13 and 14 above for further information on the Long-Term Incentive Plan.

(iii) Disclosed above are the relative proportions of each individual's remuneration that are related to performance; the remaining proportion being fixed remuneration.

For personal use only

**Next Science Limited**  
**Directors' report**  
**31 December 2024**

**KMP Remuneration (continued)**

The table below details the remuneration of KMP for the year ended 31 December 2023.

**Year ended 31 December 2023**

KMP (USD)	Cash salary and fees	Other cash benefits (ii)	Long service leave	Super- annuation	Share-based payments (options and rights) (vi)	Total	Performance Related (vii)
	\$	\$	\$	\$	\$	\$	%
<i>Executive Directors</i>							
Harry Thomas Hall, IV (I.V.)	199,038	-	-	-	-	199,038	-
Judith Mitchell (i)	204,547	-	-	11,205	-	215,752	-
<i>Non-Executive Directors</i>							
Aileen Stockburger	111,846	-	-	-	-	111,846	-
Grant Hummel	19,323	-	-	2,126	-	21,449	-
Katherine Ostin	11,401	-	-	1,254	-	12,655	-
Daniel Spira	66,439	-	-	-	-	66,439	-
Mark Compton (iii)	107,989	-	-	2,743	-	110,732	-
Bruce Hancox (iv)	30,063	-	-	3,157	-	33,220	-
<i>Other KMP</i>							
Marc Zimmerman	193,846	20,000	-	-	-	213,846	-
Matthew Myntti	360,433	8,065	-	-	45,210	413,708	10.9
Jon Swanson	264,917	449	-	-	33,229	298,595	11.1
Jacqueline Butler (v)	233,430	-	19,535	11,737	-	264,702	-
	<b>1,803,272</b>	<b>28,514</b>	<b>19,535</b>	<b>32,222</b>	<b>78,439</b>	<b>1,961,982</b>	<b>-</b>

(i) Judith Mitchell's employment with Next Science ceased on 31 July 2023.

(ii) Other cash benefits for Marc Zimmerman, Matthew Myntti and Jon Swanson include a motor vehicle allowance and/or other minor benefits.

(iii) Mark Compton ceased as a Director with Next Science on 23 August 2023.

(iv) Bruce Hancox ceased as a Director with Next Science on 30 June 2023.

(v) Jacqueline Butler's employment with Next Science ceased on 31 May 2023.

(vi) Share based payments were issued under the Company's Long-Term Incentive Plan in the form of performance rights and share options. Refer to pages 13 and 14 above for further information on the Long-Term Incentive Plan.

Disclosed above are the relative proportions of each individual's remuneration that are related to performance; the remaining proportion being fixed remuneration

**Next Science Limited**  
**Directors' report**  
**31 December 2024**

**KMP equity holdings**

The movement during the reporting period in the number of shares in Next Science Limited held directly, indirectly or beneficially, by each KMP, including their related parties, is as follows:

KMP	Balance as at 1 Jan 2024 No.	Received on exercise of options/rights No.	Other changes during the year No.*	Balance on termination	Balance as at 31 Dec 2024 No.
<i>Executive Directors</i>					
Harry Thomas Hall, IV (I.V.) (i)	200,000	465,131	-	-	665,131
<i>Non-Executive Directors</i>					
Aileen Stockburger	569,638	-	-	-	569,638
Grant Hummel	387,694	-	-	-	387,694
Katherine Ostin	-	-	-	-	-
<i>Other KMP</i>					
Marc Zimmerman	150,000	-	-	-	150,000
Matthew Myntti	4,171,824	-	-	-	4,171,824
Jon Swanson	50,000	-	-	-	50,000

\* Other changes represent shares that were purchased, sold or transferred to another party during the year.

(i) Tranche 1 Sign-on Rights vested on 10 July 2024 amounting to 465,131 shares.

This concludes the remuneration report (audited).

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors:



Aileen Stockburger

Chair

Dated at Sydney 28 February 2025





# Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of Next Science Limited

I declare that, to the best of my knowledge and belief, in relation to the audit of Next Science Limited for the financial year ended 31 December 2024 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- ii. no contraventions of any applicable code of professional conduct in relation to the audit.

KPMG

Kevin Leighton

*Partner*

Sydney

28 February 2025

For personal use only

**Next Science Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the year ended 31 December 2024**

	Note	Consolidated 2024 \$	2023 \$
Revenue	6	22,816,266	22,179,327
Cost of sales		<u>(4,372,860)</u>	<u>(5,944,751)</u>
<b>Gross profit</b>		<u>18,443,406</u>	<u>16,234,576</u>
Other income	7	105,705	99,484
Selling and distribution expenses		(16,067,483)	(20,165,335)
Research and development expenses		(5,950,269)	(6,485,524)
Administration expenses		(6,752,235)	(5,610,459)
Other expenses	9	<u>(83,233)</u>	<u>(26,827)</u>
<b>Operating loss</b>		<u>(10,304,109)</u>	<u>(15,954,085)</u>
Finance income	11	39,092	467,722
Finance costs	12	<u>(321,001)</u>	<u>(784,451)</u>
<b>Net finance costs</b>		<u>(281,909)</u>	<u>(316,729)</u>
<b>Loss before income tax expense</b>		<u>(10,586,018)</u>	<u>(16,270,814)</u>
Income tax expense	13	-	-
<b>Loss after income tax expense for the year</b>		<u>(10,586,018)</u>	<u>(16,270,814)</u>
<b>Other comprehensive loss</b>			
<i>Items that may be reclassified subsequently to profit or loss</i>			
Foreign currency translation differences	27	<u>(140,738)</u>	566,333
Other comprehensive loss for the year, net of tax		<u>(140,738)</u>	566,333
<b>Total comprehensive loss for the year</b>		<u><u>(10,726,756)</u></u>	<u><u>(15,704,481)</u></u>
		<b>Cents</b>	<b>Cents</b>
Basic earnings per share	36	(3.63)	(6.95)
Diluted earnings per share	36	(3.63)	(6.95)

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Next Science Limited**  
**Consolidated statement of financial position**  
**As at 31 December 2024**

	Note	Consolidated 2024 \$	2023 \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	14	1,673,917	9,238,697
Trade and other receivables	15	3,335,463	3,588,649
Inventories	16	726,237	721,310
Other current assets - term deposits		-	37,823
Other current assets - other	17	315,604	373,954
<b>Total current assets</b>		<u>6,051,221</u>	<u>13,960,433</u>
<b>Non-current assets</b>			
Trade and other receivables	15	36,656	36,656
Property, plant and equipment	18	519,350	713,511
Right-of-use assets	20	552,741	802,701
Intangible assets	19	2,054,153	2,387,050
<b>Total non-current assets</b>		<u>3,162,900</u>	<u>3,939,918</u>
<b>Total assets</b>		<u>9,214,121</u>	<u>17,900,351</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	21	2,659,320	3,207,184
Contract liabilities	22	274,902	274,902
Lease liabilities	24	222,314	274,801
Employee benefits	25	62,308	79,660
<b>Total current liabilities</b>		<u>3,218,844</u>	<u>3,836,547</u>
<b>Non-current liabilities</b>			
Contract liabilities	22	274,902	549,804
Loans and borrowings	23	1,806,000	-
Lease liabilities	24	464,850	687,164
Employee benefits	25	7,042	5,780
<b>Total non-current liabilities</b>		<u>2,552,794</u>	<u>1,242,748</u>
<b>Total liabilities</b>		<u>5,771,638</u>	<u>5,079,295</u>
<b>Net assets</b>		<u>3,442,483</u>	<u>12,821,056</u>
<b>Equity</b>			
Share capital	26	133,927,086	133,823,509
Reserves	27	(41,387,355)	(42,491,223)
Accumulated losses		<u>(89,097,248)</u>	<u>(78,511,230)</u>
<b>Total equity</b>		<u>3,442,483</u>	<u>12,821,056</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes*

**Next Science Limited**

ACN: 622 382 549

**Consolidated Statement of Changes in Equity**

**For the Year Ended 31 December 2024**

For personal use only

	Share capital	Common control reserve	Foreign currency translation reserve	Share option reserve	Performance rights reserve	Accumulated losses	Total equity
	\$	\$	\$	\$	\$	\$	\$
<b>Balance at 1 January 2024</b>	133,823,509	(42,596,715)	(1,301,260)	1,310,970	95,782	(78,511,230)	12,821,056
Loss for the year	-	-	-	-	-	(10,586,018)	(10,586,018)
<i>Other comprehensive income</i>							
Foreign currency translation differences	-	-	(140,738)	-	-	-	(140,738)
Total other comprehensive loss	-	-	(140,738)	-	-	-	(140,738)
Total comprehensive loss for the year	-	-	(140,738)	-	-	(10,586,018)	(10,726,756)
<i>Transactions with owners in their capacity as owners</i>							
Performance rights issued	-	-	-	-	433,473	-	433,473
Share-based payments	-	-	-	811,133	-	-	811,133
Issue of ordinary shares	100,983	-	-	-	-	-	100,983
Capital raising (costs) / refund	2,594	-	-	-	-	-	2,594
Total transactions with owners	103,577	-	-	811,133	433,473	-	1,348,183
<b>Balance at 31 December 2024</b>	<b>133,927,086</b>	<b>(42,596,715)</b>	<b>(1,441,998)</b>	<b>2,122,103</b>	<b>529,255</b>	<b>(89,097,248)</b>	<b>3,442,483</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes*

**Next Science Limited**

ACN: 622 382 549

**Consolidated Statement of Changes in Equity**

**For the Year Ended 31 December 2024**

For personal use only

	Share capital	Common control reserve	Foreign currency translation reserve	Share option reserve	Performance rights reserve	Accumulated losses	Total equity
	\$	\$	\$	\$	\$	\$	\$
<b>Balance at 1 January 2023</b>	113,526,533	(42,596,715)	(1,905,877)	2,140,298	-	(63,128,514)	8,035,725
Loss for the year	-	-	-	-	-	(16,270,814)	(16,270,814)
<i>Other comprehensive income</i>							
Foreign currency translation differences	-	-	566,333	-	-	-	566,333
Total other comprehensive loss	-	-	566,333	-	-	-	566,333
Total comprehensive loss for the year	-	-	566,333	-	-	(16,270,814)	(15,704,481)
<i>Transactions with owners in their capacity as owners</i>							
Performance rights issued	-	-	-	-	95,782	-	95,782
Share-based payments	-	-	-	38,651	-	-	38,651
Transfers to retained earnings	-	-	-	(888,098)	-	888,098	-
Foreign currency translation differences	-	-	-	20,119	-	-	20,119
Convertible note	-	-	38,284	-	-	-	38,284
Issue of ordinary shares	20,933,533	-	-	-	-	-	20,933,533
Capital raising costs	(636,557)	-	-	-	-	-	(636,557)
Total transactions with owners	20,296,976	-	38,284	(829,328)	95,782	888,098	20,489,812
<b>Balance at 31 December 2023</b>	133,823,509	(42,596,715)	(1,301,260)	1,310,970	95,782	(78,511,230)	12,821,056

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

**Next Science Limited**  
**Consolidated statement of cash flows**  
**For the year ended 31 December 2024**

	Note	Consolidated 2024 \$	2023 \$
<b>Operating activities</b>			
Receipts from customers		22,732,875	20,109,562
Payments to suppliers and employees		(29,733,440)	(33,396,827)
Payments for research and development		(1,020,543)	(1,902,656)
Interest received	11	39,092	65,398
Other income		18,613	65,527
		<u>22,732,875</u>	<u>20,109,562</u>
Net cash used in operating activities	14	<u>(7,963,403)</u>	<u>(15,058,996)</u>
<b>Investing activities</b>			
Payments for property, plant and equipment	18	(46,320)	(295,417)
Payments for intangible assets	19	(542,898)	(589,052)
(Payments for)/proceeds from investments (term deposit)		-	(34)
		<u>(589,218)</u>	<u>(884,503)</u>
Net cash used in investing activities		<u>(589,218)</u>	<u>(884,503)</u>
<b>Financing activities</b>			
Proceeds from issue of ordinary shares	26	-	14,035,576
Proceeds from borrowings	23	2,000,000	-
Proceeds from issue of converting notes		-	6,983,199
Capital raising costs	26	2,594	(637,862)
Payment of lease liabilities	20	(250,695)	(273,277)
		<u>1,751,899</u>	<u>20,107,636</u>
Net cash from financing activities		<u>1,751,899</u>	<u>20,107,636</u>
Net (decrease)/increase in cash and cash equivalents		(6,800,723)	4,164,137
Cash and cash equivalents at the beginning of the financial year		9,238,697	5,073,625
Effects of exchange rate changes on cash and cash equivalents		(764,057)	935
		<u>1,673,917</u>	<u>9,238,697</u>
<b>Cash and cash equivalents at the end of the financial year</b>		<u><u>1,673,917</u></u>	<u><u>9,238,697</u></u>

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 1. Corporate information**

Next Science Limited (the "Company") is a company domiciled in Australia.

The Group is a for-profit entity and primarily involved in the research, development and commercialisation of technologies which solve bacterial related issues.

These consolidated financial statements comprise the Company and its subsidiaries (collectively the "Group" and individually "Group companies") for the year ended 31 December 2024 and comparative information for the year ended 31 December 2023.

**Note 2. Basis of preparation**

**Statement of compliance**

The consolidated financial statements are general purpose financial statements which have been prepared in accordance with accounting standards adopted by the Australian Accounting Standards Board ("AASB") and the Corporations Act 2001. The consolidated financial statements comply with International Financial Reporting Standards ("IFRS") adopted by the International Accounting Standards Board ("IASB").

The financial statements were approved by the Board of Directors and authorised for issue on 28 February 2025.

**Basis of measurement**

The financial statements have been prepared on a historical cost basis unless otherwise stated.

**Functional and presentation currency**

The financial statements are presented in United States Dollars, which is the Group's presentation currency. Entities within the Group have functional currencies of AUD or USD as appropriate to the individual entity.

**Note 3. Material accounting policy information**

The accounting policies that are material to the Group are set out below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

**Parent entity information**

In accordance with the *Corporations Act 2001*, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 29.

**Basis of consolidation**

*(i) Business combinations*

The Group accounts for business combinations using the acquisition method when control is transferred to the Group, unless it is a combination involving entities or businesses under common control. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognised in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities.

In common control transactions assets and liabilities acquired at their book value at the date of acquisition, rather than their fair value. The difference between the fair value of the consideration given and the carrying value of the assets and liabilities acquired is recognised as a common control reserve.

The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognised in profit or loss.

*(ii) Subsidiaries*

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

**Note 3. Material accounting policy information (continued)**

*(iii) Loss of control*

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary, and any related non-controlling interest and other components of equity. Any resulting gain or loss is recognised in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

*(iv) Transactions eliminated on consolidation*

Intra-group balances and transactions, and any unrealised income and expenses arising from intra-group transactions, are eliminated. Unrealised gains arising from transactions with equity-accounted investees are eliminated against the investment to the extent of the Group's interest in the investee. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment.

**Operating segments**

Operating segments are presented using the 'management approach', where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

**Foreign currency**

*(i) Foreign currency transactions*

Transactions in foreign currencies are translated to the functional currency of the Group at exchange rates at the dates of the transactions.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Foreign currency differences are generally recognised in profit or loss and presented within finance costs.

*(ii) Foreign currency operations*

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into the presentation currency at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into the functional currency at the average exchange rates for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transaction are used.

Foreign currency differences are recognised in equity and accumulated in the translation reserve.

**Revenue from contracts with customers**

Revenue from contracts with customers is recognised when a customer obtains control of the goods or services and when performance obligations have been satisfied assessing the following criteria:

*(i) Identification of distinct elements and separate performance obligations*

In the case where the customer contract includes a sublicense and transfer of goods, the assessment must be made as to whether a separate performance obligation exists for each element. For current contracts held, whilst a license to specific IP has been given related to the Group's product, this only includes rights to distribute, not to use the IP to manufacture the product. Therefore, the licence transferred is not deemed to be a distinct element of the contract and only one performance obligation exists to transfer product to the distributor.

*(ii) Transfer of goods*

Title and control pass to some of Next Science's customers at the point when the Group fulfils its obligation to deliver, and goods are available at the customer's premises. For these customers, the performance obligation (including the license) transfers at the point in time when each good is delivered. Therefore, revenue is recognised at the point in time when the product is delivered. For other customers (including DME patients), title and control pass when the product is delivered to the courier, with revenue being recognised at this point in time.



**Note 3. Material accounting policy information (continued)**

*(iii) Measurement of transaction price*

Consideration of the contract can comprise a fixed element (upfront payment plus minimum annual purchase amounts), variable elements and cash payments.

Under AASB 15 the variable consideration is only included in the transaction price if it is 'highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur'.

In the case where cash payments are received upon signing the contract and are not subject to regulatory approval, these amounts will be initially recognised as contract liabilities to be recognised over the life of the contract once product sales have commenced. However, where the cash payments are subject to regulatory approval, for the variable consideration to be deemed 'most likely', this will only be included once regulatory approval has been received and recognised over the remaining life of the contract.

For the DME business, revenue is recognised upon receipt of cash including an estimate of amounts derived from historical reimbursements owing from Medicare and other insurer payors.

**Cost of sales**

Cost of sales includes only those costs directly attributed to provision of goods from which the Group recognises revenue. Costs include raw materials, labour, packaging and freight. The cost of sales is recognised when the performance obligation is met.

**Finance income and finance costs**

Finance income comprises interest income, dividend income and foreign currency gains. Interest income is recognised in profit or loss as it accrues using the effective interest method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instruments to the gross carrying amount of the financial asset or the amortised cost of the financial asset.

In calculating income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability. However, for financial assets that have become credit-impaired subsequent to initial recognition interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit impaired, then the calculation of interest income reverts to the gross basis.

Finance costs comprise interest expense on borrowings, lease liabilities and converting notes, foreign currency losses and impairment losses recognised on financial assets. Foreign exchange gains and losses on intercompany assets and liabilities that are not eliminated upon consolidation are recognised in other comprehensive income (OCI). Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss using the effective interest method.

Interest expenses includes interest in relation to lease liabilities and is calculated based on the bank borrowing rate as appropriate for the lease contract, with a range of 3.5% to 4.6% on current leases held.

Foreign currency gains and losses are reported on a net basis as either finance income or finance cost depending on whether foreign currency movements are in a net gain or net loss position.

**Income tax**

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in OCI.

The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received.

**Note 3. Material accounting policy information (continued)**

*(i) Current tax*

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any tax liability arising from dividends.

Current tax assets and liabilities are offset only if certain criteria are met.

*(ii) Deferred tax*

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognised for temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, or on taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognised for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date.

The measurement of deferred tax reflects the tax consequences that could follow the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if certain criteria are met.

**Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no right at the end of the reporting period to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

**Cash and cash equivalents**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position.

**Trade and other receivables**

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

**Note 3. Material accounting policy information (continued)**

The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

**Inventories**

Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on the first in, first out principle. Inventory provision is measured by taking into consideration inventory quantities held, timing of expiration of products and confirmed sale contracts. The amount of any inventory write-down to net realisable value or inventory losses is recognised as an expense in the period the write-down or loss occurred.

**Property, plant and equipment**

*(i) Recognition and measurement*

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. If significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the consolidated entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Any revaluation surplus reserve relating to the item disposed of is transferred directly to retained profits.

*(ii) Subsequent expenditure*

Subsequent expenditure is capitalised only when it is probable that the future economic benefits associated with the expenditure will flow to the Group.

*(iii) Depreciation*

Depreciation is calculated based on the cost of property, plant and equipment less their estimated residual values using the straight-line basis over their estimated useful lives, and is generally recognised in profit or loss. Right-of-use assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Group will obtain ownership by the end of the lease term.

The estimated useful lives of property, plant and equipment are as follows:

<b>Fixed asset class</b>	<b>Useful life</b>
Leasehold improvements	5-15 years
Plant and equipment	5 years
Furniture and fittings	5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

**Right-of-use assets**

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

**Note 3. Material accounting policy information (continued)**

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

**Intangible assets**

*(i) Recognition and measurement*

*Research and development expenditure*

Expenditure on research activities is recognised in profit or loss as incurred. Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. Otherwise, it is recognised in profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortisation and any accumulated impairment losses.

*Patents*

Expenditure is capitalised in relation to patent application costs and amortised over the remaining life of the base patent as relevant. Costs will be no longer capitalised in the event that a patent application is no longer being pursued with any existing capitalised costs being impaired as an expense in the profit or loss.

*Computer software*

Computer software comprises computer application system software and licenses.

*(ii) Subsequent expenditure*

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in profit or loss as incurred.

*(iii) Amortisation*

Amortisation is calculated based on the cost of intangible assets less their estimated residual values using the straight-line method over their estimated useful lives and is generally recognised in profit or loss.

The estimated useful lives of intangible assets are as follows:

- Development expenditure: 5 years
- Computer software: 2-3 years
- Patents: 8-15 years

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Intangible assets, other than trademarks and goodwill, have finite useful lives.

**Trade and other payables**

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature, they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

**Contract liabilities**

Contract liabilities represent the Group's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the Group recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Group has transferred the goods or services to the customer.

**Note 3. Material accounting policy information (continued)**

**Borrowings**

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

**Leases**

*(i) Definition of a lease*

The determination of whether a contract contains a lease is on the basis of whether the customer has the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has applied this definition to all lease contracts currently held.

*(ii) Lessee accounting*

For all contracts determined to constitute a lease, right-of-use assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments. When measuring these lease liabilities, the Group discounted lease payments using the interest rate implicit in the lease contract.

Right-of-use assets are tested for impairment in accordance with AASB 136 Impairment of assets. Lease incentives, if relevant, are recognised as part of the measurement of the right-of-use assets and lease liabilities. Depreciation is expensed on right-of-use assets and interest on lease liabilities, both recognised in the consolidated statement of profit or loss.

For presentation purposes, the total amount of cash paid in relation to leases is separated into a principal portion (presented within financial activities) and interest on lease liabilities, both recognised in the consolidated statement of profit or loss.

For short-term leases (lease term of 12 months or less) and leases of low-value assets, the Group has opted to recognise a lease expense on a straight-line basis. This expense is presented within other expenses in the consolidated statement of profit or loss.

**Finance costs**

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

**Provisions**

A provision is recognised if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably and if it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as a finance cost.

**Employee benefits**

*(i) Short-term employee benefits*

Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled within 12 months of the end of the financial year in which employees render the related service. Short-term employee benefits include salaries and wages plus related on-costs such as payroll tax, superannuation and workers compensation insurance and are measured at the undiscounted amounts expected to be paid when the obligation is settled.

*(ii) Long-term employee benefits*

Long-term employee benefits include employees' long service leave and annual leave entitlements not expected to be settled within 12 months of the end of the financial year in which employees render the related service. Other long-term employee benefits are measured at the present value of the expected future payments to be made to employees. Expected future payments incorporate anticipated future wage and salary levels, duration of service and employee departures and are discounted at rates determined by reference to market yields at the end of the reporting period on corporate bonds that have maturity dates that approximate the terms of the obligations. Any remeasurements for changes in assumptions of obligations for long-term employee benefits are recognised in profit or loss in the periods in which the changes occur.

**Note 3. Material accounting policy information (continued)**

*(iii) Defined contribution plans*

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to employees' defined contribution plans are recognised as an expense as the related service is provided. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in future payments is available.

*(iv) Share-based payment arrangements*

The fair value of performance rights and options granted is recognised as an employee expense with a corresponding increase in equity, on a straight-line monthly basis over the vesting period in which the performance and/or service conditions are fulfilled after which the employee becomes unconditionally entitled to them. The cumulative expense recognised for share-based payments at each reporting date until the vesting date reflects the extent to which the vesting period has ended and the Group's best estimate of the number of equity instruments that will ultimately vest. The expense or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of the period. No expense is recognised for awards that do not ultimately vest, except for equity-settled transactions for which vesting are conditional upon a market or non-vesting condition. These are treated as vesting irrespective of whether or not the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

**Financial instruments**

*(i) Recognition and initial measurement*

The Group initially recognises trade receivables issued on the date that they are originated. All other financial assets and financial liabilities are recognised initially on the trade date.

*(ii) Classification and subsequent measurement*

*Financial assets*

On initial recognition, a financial asset is classified as measured at amortised cost or fair value through profit or loss ("FVTPL").

Financial assets at amortised cost are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

*Financial liabilities*

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

*(iii) Derecognition*

*Financial assets*

The Group derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability.

*Financial liabilities*

The Group derecognises a financial liability when its contractual obligations are discharged, cancelled or expired.

**Note 3. Material accounting policy information (continued)**

*(iv) Offsetting*

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

**Impairment**

The Group recognises loss allowances for expected credit losses ("ECL") on financial assets and contract assets. Loss allowances where relevant are measured at an amount equal to a 12 month ECL.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECL's, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Group's historical experience and informed credit assessment and including forward-looking information.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 90 days past due.

The Group considers a financial asset to be in default when the borrower is unlikely to pay its obligations to the Group in full or the financial asset is more than 130 days past due.

ECLs are a probability-weighted estimate of credit losses and are measured as the present value of all cash shortfalls discounted at the effective interest rate. Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount.

An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognised in profit or loss and reflected in an allowance account against loans and receivables. Interest on the impaired asset continues to be recognised. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

**Share capital**

*Ordinary shares*

Incremental costs directly attributable to the issue of ordinary shares, net of any tax effects, are recognised as a deduction from equity.

**Fair value measurement**

'Fair value' is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Group has access at that date. The fair value of a liability reflects its non-performance risk.

A number of the Group's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. When one is available, the Group measures the fair value using the quoted price in an active market. A market is regarded as 'active' if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no quoted price in an active market, then the Group uses valuation techniques that maximise the use of relevant observable inputs and minimise the use of unobservable inputs.

The chosen valuation technique incorporates all of the factors that market participants would consider in pricing a transaction.

**Earnings per share**

*(i) Basic earnings per share*

Basic earnings per share is calculated by dividing the profit or loss attributable to the owners of the Company excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

**Note 3. Material accounting policy information (continued)**

*(ii) Diluted earnings per share*

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

**Goods and Services Tax ('GST') and other similar taxes**

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

**Note 4. Critical accounting judgements, estimates and assumptions**

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income, expenses and disclosure of contingent liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

The key judgements, estimates and assumptions are discussed below:

*Revenue from DME business*

For the DME business, revenue is recognised upon receipt of cash including an estimate of amounts derived from historical reimbursements owing from Medicare and other insurer payors.

*Going concern*

The financial report has been prepared on a going concern basis, which assumes continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business for a period of at least twelve months from the date this financial report is approved.

For the financial year ended 31 December 2024 the Group incurred a loss of \$10,586,018 and had net cash outflows from operations of \$7,963,403. As at 31 December 2024, the Group had net current asset and net asset positions of \$2,832,377 and \$3,442,483, respectively.

The Group has modelled a range of scenarios for going concern purposes including improvement in the Group's direct sales and distribution model. The Group restructured the direct sales force team during the year and implemented a unified field strategy for its XBIO™ product suite and the restructuring of its Durable Medical Equipment (DME) sales force and go-to-market strategy providing a more variable cost structure for the Group. Furthermore, on 17 July 2024, the Group entered into a facility agreement with TIGA Trading Pty Ltd (a company associated with Thorney Investment Group) (Thorney) to provide a US\$5 million unsecured loan facility with a maturity date of 17 July 2026 (Facility). The total amount drawn down on the Facility as at 31 December 2024 amounted to US\$2 million. The Group considers that its cash and term deposits totalling \$1,673,917 at 31 December 2024, together with the remaining Facility of US\$3 million and further potential cost management initiatives are sufficient to enable the Group to continue as a going concern for the foreseeable future, being at least twelve months from the date of signing this financial report.



**Note 5. Standards issued but not yet effective**

A number of new standards are effective for annual periods beginning after 1 January 2024 and earlier application is permitted; however, the Group has not early adopted the new or amended standards in preparing these consolidated financial statements.

The Group plans to apply the amendments when they become effective and they are not expected to have a significant impact on the Group's consolidated financial statements:

- AASB 2024-2 Amendments to Australian Accounting Standards – Classification and Measurement of Financial Instruments – effective date 1 January 2026
- AASB 18 *Presentation and Disclosure in Financial Statements* – effective date 1 January 2027

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 6. Revenue**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Revenue from contracts with customers	<u>22,816,266</u>	<u>22,179,327</u>

*Identification of reporting operating segments*

The Group operates in one operational segment and measures performance based on profit or loss before tax, based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers (CODM)) in assessing performance and in determining the allocation of resources. The one operating segment operates over two geographies, North America and Australia and New Zealand.

	<b>North America \$</b>	<b>Australia and New Zealand \$</b>	<b>Total \$</b>
<b>Year ended 31 December 2024</b>			
Revenue from contracts with customers	22,067,197	749,069	22,816,266
Segment assets	5,719,618	3,494,503	9,214,121
Segment liabilities	2,786,905	2,984,733	5,771,638
Segment loss	5,824,370	4,761,648	10,586,018

	<b>North America \$</b>	<b>Australia and New Zealand \$</b>	<b>Total \$</b>
<b>Year ended 31 December 2023</b>			
Revenue from contracts with customers	21,836,283	343,144	22,179,327
Segment assets	5,893,600	12,016,395	17,900,351
Segment liabilities	3,764,477	1,324,462	5,079,295
Segment loss	9,969,090	6,301,724	16,270,814

*Major customers*

Revenues from two major customers of the Group represented 20% (2023: 23%) of the Group's total revenue.

**Note 7. Other income**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Other income	<u>105,705</u>	<u>99,484</u>

For personal use only

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 8. Depreciation and amortisation**

The loss from ordinary activities before income tax includes the following expenses:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<b>Included in selling and distribution expenses</b>		
Depreciation and amortisation	60,793	64,853
<b>Included in research and development expenses</b>		
Depreciation and amortisation	970,038	796,252
<b>Included in administrative expenses</b>		
Depreciation and amortisation	242,403	251,918

**Note 9. Other expenses**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Loss on sale of fixed asset	-	81
Impairment loss on intangibles	83,233	26,746
	<u>83,233</u>	<u>26,746</u>
	<u><u>83,233</u></u>	<u><u>26,827</u></u>

**Note 10. Employee expenses**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Salaries and wages	12,880,150	17,569,111
Contributions to defined contribution funds	11,116	49,357
Share-based payments	1,008,441	134,433
	<u>13,899,707</u>	<u>17,752,901</u>

As part of employee compensation, the Group offers medical insurance to certain employees in certain geographies (2024:\$1,733,826, 2023:\$1,870,405). These insurance amounts are not included in the above figures.

**Note 11. Finance income**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Interest income	39,092	65,398
Gain on modification and early conversion of convertible note	-	402,324
	<u>39,092</u>	<u>467,722</u>

For personal use only

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 12. Finance costs**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Interest expense on lease liabilities	37,067	48,536
Interest expense on convertible note	-	712,694
Interest on unsecured loan facility	170,938	-
Other interest expense	8,191	876
Net foreign exchange loss	104,805	22,345
	<u>321,001</u>	<u>784,451</u>

**Note 13. Income tax benefit**

Income tax expense comprises current and deferred tax expense and is recognised in profit or loss, except to the extent that it relates to a business combination or items recognised directly in equity or other comprehensive income. The components of tax expense comprise:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Income tax benefit</i>		
Current tax	-	-
Deferred tax	-	-
Aggregate income tax expense	<u>-</u>	<u>-</u>
<i>Numerical reconciliation of income tax benefit and tax at the statutory rate</i>		
Reconciliation of income tax to accounting profit:		
Loss before income tax expense	(10,586,018)	(16,270,814)
Tax at the statutory tax rate of 25%	(2,646,505)	(4,067,704)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Permanent differences	295,840	33,608
Effect of tax rate in foreign jurisdictions	(209,419)	(412,563)
Tax losses not brought to account	2,560,084	4,446,659
Income tax benefit	<u>-</u>	<u>-</u>

The unused tax losses not recognised as at 31 December were as follows:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Australia gross unused tax losses (in AUD)	69,879,671	63,277,349
USD gross unused tax losses (in USD)	47,672,493	44,809,849

Tax losses are recognised only to the extent that it is probable that the future taxable profit will be available against which the benefits can be utilised. Management has considered all the facts and circumstances and believe there is no material uncertainty over the availability of the tax losses.

**Australian entities**

Movement in deferred tax assets and liabilities using the Company's domestic Australian tax rate of 25%

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 13. Income tax benefit (continued)**

	Opening balance \$	Recognised in profit or loss \$	Closing balance \$
<b>2024 cost</b>			
Intangibles	(519,960)	71,991	(447,969)
Employee benefits	8,028	538	8,566
Accrued expenses	54,615	20,275	74,890
Deferred revenue	206,176	(68,725)	137,451
Unused tax losses carried forward	10,305,543	1,089,912	11,395,455
Rights of use assets	(13,007)	2,649	(10,358)
Lease Liabilities	13,262	(589)	12,673
Other items	(46,998)	(11,040)	(58,038)
Deferred tax assets not recognised	(10,007,659)	(1,105,011)	(11,112,670)
<b>Deferred tax assets/(liabilities)</b>	<u>-</u>	<u>-</u>	<u>-</u>

<b>2023 cost</b>			
Intangibles	(514,447)	(5,513)	(519,960)
Employee benefits	25,193	(17,166)	8,027
Accrued expenses	32,644	21,971	54,615
Deferred revenue	274,902	(68,726)	206,176
Unused tax losses carried forward	8,508,385	1,795,181	10,303,566
Other items	(52,272)	5,529	(46,743)
Deferred tax assets not recognised	(8,274,405)	(1,731,276)	(10,005,681)
<b>Deferred tax assets/(liabilities)</b>	<u>-</u>	<u>-</u>	<u>-</u>

**US entities**

Movement in deferred tax assets and liabilities using the US tax rate of 21%

	Opening balance \$	Recognised in profit or loss \$	Closing balance \$
<b>2024 cost</b>			
Intangibles	(64,514)	9,436	(55,078)
Employee benefits	11,200	(3,831)	7,369
Accrued expenses	302,389	(127,148)	175,241
Unused tax losses carried forward	9,410,068	1,099,451	10,509,519
Rights of use assets	(52,496)	7,247	(45,249)
Lease Liabilities	1,336	90,527	91,863
Other items	(36,626)	3,456	(33,170)
Deferred tax asset not recognised	(9,571,357)	(1,079,138)	(10,650,495)
<b>Deferred tax assets/(liabilities)</b>	<u>-</u>	<u>-</u>	<u>-</u>

<b>2023 cost</b>			
Intangibles	(73,950)	9,436	(64,514)
Employee benefits	5,089	6,111	11,200
Accrued expenses	156,307	146,082	302,389
Unused tax losses carried forward	7,244,113	2,165,955	9,410,068
Other items	(28,418)	(59,368)	(87,786)
Deferred tax asset not recognised	(7,303,141)	(2,268,216)	(9,571,357)
<b>Deferred tax assets/(liabilities)</b>	<u>-</u>	<u>-</u>	<u>-</u>

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 14. Cash and cash equivalents**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Cash at bank	1,673,917	9,238,697

**Reconciliation of cash flows from operating activities**

	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Loss for the year	(10,586,018)	(16,270,814)
<b>Adjustments for:</b>		
Depreciation and amortisation	1,273,234	1,113,023
Share based payments (note 10)	1,008,441	134,433
Unrealised foreign currency translation gain	74,567	24,251
Interest expense on right-of-use assets (note 20)	37,067	48,536
Interest expense on convertible notes	-	712,694
Gain on remeasurement on the early conversion of convertible note	-	(402,324)
Sub-lease income	(61,355)	(33,510)
Loss on sale of fixed asset (note 9)	-	81
Impairment of intangible assets (note 19)	83,233	26,746
Interest on loan facility	170,938	-
Other	7,792	-
<b>Operating loss before changes in working capital and provisions</b>	<b>(7,992,101)</b>	<b>(14,646,884)</b>
<b>Change in operating assets and liabilities</b>		
Change in trade and other receivables	252,974	(1,909,282)
Change in inventories	4,651	273,056
Change in other current assets	619,502	312,778
Change in trade and other payables	(547,857)	1,348,902
Change in provisions	(25,670)	(162,664)
Change in contract liabilities	(274,902)	(274,902)
	28,698	(412,112)
<b>Net cash used in operating activities</b>	<b>(7,963,403)</b>	<b>(15,058,996)</b>

**Note 15. Trade and other receivables**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Trade receivables	3,314,827	3,460,703
Other receivables	20,636	127,946
	<b>3,335,463</b>	<b>3,588,649</b>
<i>Non-current assets</i>		
Security deposit	36,656	36,656

The carrying value of receivables is considered a reasonable approximation of fair value due to the short-term nature of the balances. The Group has assessed any potential credit risk associated with these counterparties and deemed expected credit loss to be insignificant.

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 15. Trade and other receivables (continued)**

Information about the Group's exposure to credit and market risks, and impairment losses for trade receivables is included in Note 37 (c).

**Note 16. Inventories**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Finished goods - at cost	363,626	385,565
Raw materials – at cost	362,678	345,391
Less: Provision for obsolete stock	(67)	(9,646)
	<u>726,237</u>	<u>721,310</u>

**Note 17. Other current assets - other**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current assets</i>		
Prepayments and other assets	<u>315,604</u>	<u>373,954</u>

**Note 18. Property, plant and equipment**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Leasehold improvements - at cost	385,179	406,284
Less: Accumulated depreciation	(167,063)	(134,766)
	<u>218,116</u>	<u>271,518</u>
Plant and equipment - at cost	1,330,620	1,329,939
Less: Accumulated depreciation and impairment	(1,125,007)	(1,020,670)
	<u>205,613</u>	<u>309,269</u>
Furniture, fixtures and fittings - at cost	394,580	388,971
Less: Accumulated depreciation and impairment	(298,959)	(256,247)
	<u>95,621</u>	<u>132,724</u>
	<u>519,350</u>	<u>713,511</u>

For personal use only

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 18. Property, plant and equipment (continued)**

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

<b>Consolidated</b>	<b>Leasehold improvements \$</b>	<b>Plant and equipment \$</b>	<b>Furniture and fittings \$</b>	<b>Total \$</b>
Balance at 1 January 2023	276,211	339,700	80,937	696,848
Additions	45,042	148,215	102,079	295,336
Depreciation expense	(49,735)	(178,646)	(50,292)	(278,673)
Balance at 1 January 2024	271,518	309,269	132,724	713,511
Additions	-	40,710	5,610	46,320
Disposals	-	(8,516)	-	(8,516)
Depreciation expense	(53,402)	(135,850)	(42,713)	(231,965)
Balance at 31 December 2024	<u>218,116</u>	<u>205,613</u>	<u>95,621</u>	<u>519,350</u>

**Note 19. Intangible assets**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Capitalised development - at cost	2,797,150	2,569,723
Less: Accumulated amortisation and impairment	(1,571,152)	(1,145,925)
	<u>1,225,998</u>	<u>1,423,798</u>
Patents and trademarks - at cost	1,919,970	1,807,655
Less: Accumulated amortisation and impairment	(1,091,815)	(844,403)
	<u>828,155</u>	<u>963,252</u>
Computer software - at cost	56,772	56,772
Less: Accumulated amortisation	(56,772)	(56,772)
	<u>-</u>	<u>-</u>
	<u>2,054,153</u>	<u>2,387,050</u>

For personal use only



**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 19. Intangible assets (continued)**

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

<b>Consolidated</b>	<b>Capitalised development \$</b>	<b>Patents and trade marks \$</b>	<b>Computer software \$</b>	<b>Total \$</b>
Balance at 1 January 2023	1,368,578	1,041,352	-	2,409,930
Additions	457,029	132,023	-	589,052
Impairment of assets	(26,746)	-	-	(26,746)
Amortisation expense	(375,063)	(210,123)	-	(585,186)
Balance at 1 January 2024	1,423,798	963,252	-	2,387,050
Additions	430,583	112,315	-	542,898
Impairment of assets	(83,233)	-	-	(83,233)
Amortisation expense	(545,150)	(247,412)	-	(792,562)
Balance at 31 December 2024	<u>1,225,998</u>	<u>828,155</u>	-	<u>2,054,153</u>

**Note 20. Right-of-use assets**

The Group holds leases for properties with lease terms ranging from 3 to 5 years.

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current assets</i>		
Property - right-of-use	1,681,118	1,682,369
Less: Accumulated depreciation	<u>(1,128,377)</u>	<u>(879,668)</u>
	<u>552,741</u>	<u>802,701</u>

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Amounts recognised in profit or loss</i>		
Depreciation expense	248,707	249,164
Interest expense	37,067	48,536
Expense relating to variable lease payments not included in the measurement of the lease liability	<u>34,131</u>	<u>109,763</u>
	<u>319,905</u>	<u>407,463</u>

The total cash outflow in relation to lease payments amounted to \$250,695 (2023: \$273,277).

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 20. Right-of-use assets (continued)**

<b>Movement</b>	<b>Property \$</b>
Balance at 1 January 2024	802,701
Depreciation expense	(248,707)
Foreign exchange movements	(1,253)
<b>Closing value at 31 December 2024</b>	<u>552,741</u>
Balance at 1 January 2023	1,053,113
Depreciation expense	(249,164)
Foreign exchange movements	(1,248)
<b>Closing value at 31 December 2023</b>	<u>802,701</u>

**Note 21. Trade and other payables**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Trade payables	928,050	1,411,037
Other payables and accrued expenses	1,731,270	1,796,147
	<u>2,659,320</u>	<u>3,207,184</u>

All amounts are short term and the carrying values are considered to be a reasonable approximation of fair value.

**Note 22. Contract liabilities**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Contract liabilities	<u>274,902</u>	<u>274,902</u>
<i>Non-current liabilities</i>		
Contract liabilities	<u>274,902</u>	<u>549,804</u>

Contract liabilities relate to consideration received in advance from customers for which revenue will be recognised as and when products are delivered or other performance obligations met.

**Note 23. Loans and borrowings**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Non-current liabilities</i>		
Loan Facility (i)	1,806,000	-
	<u>1,806,000</u>	<u>-</u>

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 23. Loans and borrowings (continued)**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<b>Movements:</b>		
Balance at 1 January 2024	-	-
Proceeds from Facility (i)	2,000,000	-
<b>Less:</b>		
Fair value of options (ii)	(393,899)	-
Net amount	<u>1,606,101</u>	-
<b>Add:</b>		
Interest	116,985	-
Amortisation of options	<u>82,914</u>	-
Balance at 31 December 2024	<u><u>1,806,000</u></u>	-

(i) On 17 July 2024, the Group announced that it had entered into a facility agreement with TIGA Trading Pty Ltd (a company associated with Thorney Investment Group) (Thorney) to provide a US\$5 million unsecured loan facility with a maturity date of 17 July 2026 (Facility). The Facility provides a buffer against unexpected financial challenges and flexibility to respond should investment opportunities arise. Interest is payable at 12% per annum on amounts drawn under the Facility and accrued interest is payable on the earlier of the Facility termination date and the date the principal outstanding is repaid in full. The total amount drawn down on the Facility as at 31 December 2024 amounted to US\$2 million. In conjunction with the execution of the Facility Agreement, the parties signed an option deed under which Next Science agreed to issue to Thorney 5 million unquoted options over ordinary shares in the Company at an exercise price of A\$0.42 and with a three-year expiry. The 5 million options were issued on 17 July 2024.

(ii) The conversion options may be exercised by Thorney at any time until maturity. When the conversion option is exercised, the outstanding principal of the notes are converted into ordinary shares of the Group; any accrued but unpaid interest as at the exercise date is required to be paid in cash. Otherwise, the total principal and accrued interest outstanding is repayable in cash at maturity.

**Note 24. Lease liabilities**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Lease liability	<u>222,314</u>	<u>274,801</u>
<i>Non-current liabilities</i>		
Lease liability	<u>464,850</u>	<u>687,164</u>

The following table sets out a maturity analysis of lease payments, showing the undiscounted lease payments to be paid after the reporting date:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Maturity analysis</i>		
Not later than 1 year	267,753	259,979
Later than 1 year but not later than 5 years	<u>463,258</u>	<u>755,311</u>
	<u><u>731,011</u></u>	<u><u>1,015,290</u></u>

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 25. Employee benefits**

	<b>Consolidated</b>	<b>Consolidated</b>
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Current liabilities</i>		
Liability for annual leave	<u>62,308</u>	<u>79,660</u>
<i>Non-current liabilities</i>		
Liability for long service leave	<u>7,042</u>	<u>5,780</u>

**Note 26. Share capital**

	<b>Fully paid</b>
<b>In, number of shares</b>	
Balance as at 1 January 2023	214,790,134
Institutional placement in September 2023 (i), (ii)	28,571,429
Share Purchase Plan in September 2023 (ii)	20,238,012
US Placement in September 2023 (ii)	2,244,504
Shares issued for corporate advisory services in November 2023 (iii)	142,857
Director Placement in November 2023 (iv)	1,034,325
Shares issued to Walker Group in November 2023 on redemption of A\$10 million convertible notes (iv)	<u>24,673,842</u>
<b>Balance as at 31 December 2023</b>	<u>291,695,103</u>
Shares issued to CEO and Managing Director	465,131
<b>Balance as at 31 December 2024</b>	<u>292,160,234</u>
	<b>Fully paid</b>
	<b>\$</b>
Balance at 1 January 2023	113,526,533
Institutional placement in September 2023 (i), (ii)	7,777,143
Share Purchase Plan in September 2023 (ii)	5,508,787
US Placement in September 2023 (ii)	610,954
Shares issued for corporate advisory services in November 2023 (iii)	38,886
Directors Placement in November 2023 (iv)	281,543
Shares issued to Walker Group in November 2023 on redemption of A\$10 million convertible notes (iv)	6,716,220
Capital raising costs	(636,557)
<b>Balance at 31 December 2023</b>	<u>133,823,509</u>
Shares issued to CEO and Managing Director (v)	100,983
Capital raising costs (refund)	2,594
<b>Balance at 31 December 2024</b>	<u>133,927,086</u>

(i) In August 2023, Next Science completed a placement to institutional and sophisticated investors (**Placement**) at a price of A\$0.42 (**Placement Price**).

(ii) In September 2023, Next Science issued:

- a. 28,571,429 ordinary fully paid shares to the participants in the Placement, raising A\$12 million (before costs);
- b. 20,238,012 ordinary fully paid shares raising A\$8,499,965 via a Share Purchase Plan (SPP) at the Placement Price;
- c. 2,244,504 ordinary fully paid shares raising A\$610,954 via an offer to eligible US investors at the Placement Price (US Offer).

(iii) In November 2023, Next Science issued 142,857 ordinary fully paid shares at the Placement Price to a consultant, who provided corporate advisory services to the Company, in lieu of fees.

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 26. Share capital (continued)**

- (iv) In November 2023, following receipt of shareholder approval at a General Meeting held on 25 October 2023, :
- Next Science issued 1,034,325 ordinary fully paid shares to three Directors (Chair Aileen Stockburger, Managing Director and CEO I.V. Hall, and Non-Executive Director, Grant Hummel) who participated in the Placement and US Offer; and
  - Next Science issued 24,673,842 ordinary fully paid shares to Walker Group Holdings Pty Limited at the Placement Price in accordance with the Subscription and Redemption Deed between Walker Group Holdings Pty Limited and Next Science on the basis that the redemption amount of A\$10m plus accrued interest was offset against the share subscription commitment and the A\$10m convertible notes held by Walker Group were to be retired; and
  - the A\$10m convertible notes held by Walker Group were retired in accordance with the Subscription and Redemption Deed.
- (v) On 26 July 2024 tranche 1 of the Sign-on Rights held by the Managing Director and CEO, I.V. Hall, vested and 465,131 ordinary shares were issued to I.V. Hall in equity settlement of tranche 1.

*Ordinary shares*

Fully paid ordinary shares

Ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the number of shares held. At shareholders' meetings, each ordinary share is entitled to one vote when a poll is called.

*Capital management*

The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

**Note 27. Reserves**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	\$	\$
Share option reserve	2,122,103	1,310,970
Foreign currency translation reserve	(1,441,998)	(1,301,260)
Common control reserve	(42,596,715)	(42,596,715)
Performance rights reserve	529,255	95,782
	<u>(41,387,355)</u>	<u>(42,491,223)</u>

*Foreign currency translation reserve*

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations where their functional currency is different to the Group's presentation currency.

*Common control reserve*

The acquisition of the share capital of Microbial Defense Systems Holdings Inc ("MDS") by the Company on 22 December 2017 was accounted for as a common control transaction. As a consequence, the difference between the fair value of the consideration paid (\$43,862,500) and the existing book values of assets and liabilities of MDS (\$1,265,785) was debited to a common control reserve, directly within equity.

*Share option reserve*

The share option reserve comprises the value of the share-based payment arrangements recognised in equity.

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 27. Reserves (continued)**

*Movements in reserves*

Movements in each class of reserve during the current and previous financial year are set out below:

<b>Consolidated</b>	<b>Share option reserve \$</b>	<b>Foreign currency translation reserve \$</b>	<b>Common control reserve \$</b>	<b>Performance rights reserve \$</b>	<b>Total \$</b>
Balance at 1 January 2023	2,140,298	(1,905,877)	(42,596,715)	-	(42,362,294)
Foreign currency translation	-	566,333	-	-	566,333
Performance rights issued	-	-	-	95,782	95,782
Share-based payments	38,651	-	-	-	38,651
Transfers to retained earnings	(888,098)	-	-	-	(888,098)
Foreign currency translation differences	20,119	-	-	-	20,119
Convertible note	-	38,284	-	-	38,284
<b>Balance at 31 December 2023</b>	<b>1,310,970</b>	<b>(1,301,260)</b>	<b>(42,596,715)</b>	<b>95,782</b>	<b>(42,491,223)</b>
Foreign currency translation	-	(140,738)	-	-	(140,738)
Performance rights issued	-	-	-	433,473	433,473
Share-based payments	811,133	-	-	-	811,133
<b>Balance at 31 December 2024</b>	<b><u>2,122,103</u></b>	<b><u>(1,441,998)</u></b>	<b><u>(42,596,715)</u></b>	<b><u>529,255</u></b>	<b><u>(41,387,355)</u></b>

**Note 28. Dividends**

*Dividends*

No dividends were paid or declared by the Company during the financial year.

**Note 29. Parent entity information**

As at, and throughout, the financial year to 31 December 2024 the parent entity of the Group was Next Science Limited.

*Statement of profit or loss and other comprehensive income*

	<b>Parent 2024 \$</b>	<b>Parent 2023 \$</b>
(Loss)/profit after income tax	(32,618,251)	1,474,963
Other comprehensive (loss)/income	(1,467,256)	901,312
<b>Total comprehensive (loss)/income</b>	<b><u>(34,085,507)</u></b>	<b><u>2,376,275</u></b>

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 29. Parent entity information (continued)**

*Statement of financial position*

	<b>Parent 2024</b>	<b>Parent 2023</b>
	<b>\$</b>	<b>\$</b>
<i>Assets</i>		
Total current assets	3,987,884	3,299,432
Total non-current assets	3,442,482	33,204,079
<b>Total assets</b>	<u>7,430,366</u>	<u>36,503,511</u>
<i>Liabilities</i>		
Total current liabilities	(3,375,826)	(1,517,647)
Total non-current liabilities	(1,806,000)	-
<b>Total liabilities</b>	<u>(5,181,826)</u>	<u>(1,517,647)</u>
<b>Total net assets</b>	<u>2,248,540</u>	<u>34,985,864</u>
<i>Equity</i>		
Share capital	133,927,086	133,823,509
Share option reserve	2,122,103	1,310,970
Performance rights reserve	529,255	95,781
Common control reserve	(27,257,549)	(27,257,549)
Converting notes reserve	-	45,146
Foreign currency translation reserve	(2,203,104)	(780,994)
Accumulated losses	(104,869,251)	(72,250,999)
<b>Total equity</b>	<u>2,248,540</u>	<u>34,985,864</u>

*Guarantees entered into by the parent entity in relation to the debts of its subsidiaries*

The parent entity had no guarantees as at 31 December 2024 and 31 December 2023.

*Contingent liabilities*

The parent entity had no contingent liabilities as at 31 December 2024 and 31 December 2023.

*Capital commitments - Property, plant and equipment*

The parent entity had no capital commitments for property, plant and equipment as at 31 December 2024 and 31 December 2023.


*Material accounting policy information*

The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 3, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.

**Note 30. Group entities**

Set out below is the Group structure listing all subsidiaries as at 31 December 2024.



**Note 31. Related party transactions**

**(a) Key management personnel compensation**

Key management personnel ("KMP") are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly and indirectly, and include the Directors, executive and non-executive, as well as certain other senior executives. The totals of remuneration of the KMP of the Company included within employee expenses are as follows:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Short term employee benefits	1,871,122	1,831,786
Other long term employee benefits	-	19,535
Post employment benefits	6,992	32,222
Share based payment benefits	742,670	78,439
<b>Total</b>	<b>2,620,784</b>	<b>1,961,982</b>

*Short term employee benefits*

Short term employee benefits includes salary, fringe benefits and cash bonuses paid to the executive directors and other KMP as well as fees and benefits awarded to the non-executive directors.

*Post-employment benefits*

Post-employment benefits are the cost of superannuation contributions made during the year.



**Note 31. Related party transactions (continued)**

**(b) Key management personnel transactions**

KMPs of the Company hold 0.33% (2023: 0.59%) of the issued capital of the Company as at 31 December 2024.

**Note 32. Share based employee incentive arrangements**

*Equity Incentive Plan (equity-settled)*

At the time of the Company's IPO, the Company established a long-term incentive plan (LTI Plan) under which the Company could issue equity incentives to eligible executives of the Company. During 2023, the Board undertook a review of the Company's approach to long-term incentives, assisted by external remuneration consultants, with the key objectives of the review including ensuring that the Company's LTI Plan was appropriate for the size of the Company and its stage of development, the LTI Plan was aligned to the Company's strategy and commercialisation goals and the LTI Plan was simple to understand and valuable to all participants.

This review led to the Board revising the Company's LTI Plan in 2023 with a key change being the form of equity offered under the LTI Plan. Whereas previously the LTI Plan offered participants performance rights only, the LTI Plan now offers participants an equal split of performance rights and options ie. 50% performance rights and 50% options.

The grant of equity under the LTI Plan is governed by the Next Science Employee Equity Plan Rules.

The eligible participants in the 2024 LTI Plan were the CEO, CFO, CTO, COO, Senior Vice-President Sales, VP Product Development, VP Clinical & Regulatory Affairs, and VP Operations.

On 24 July 2023, 7,366,333 options and 2,629,928 Performance Rights were issued under the Company's 2023 LTI Plan to members of the executive team who had been with the Company for more than 12 months. Similarly, on 3 May 2024, 3,361,855 options and 1,814,394 Performance Rights were issued; and on 16 September 2024, 16,788,699 options and 8,623,423 Performance Rights were issued under the Company's 2024 LTI Plan to members of the executive team who had been with the Company for more than 12 months.

The number of Performance Rights granted under the 2024 LTI Plan was based on the volume weighted average price (VWAP) of shares in the Company during the 30 days to 30 June in the relevant plan year.

The vesting of Performance Rights issued under the 2024 LTI Plan is dependent on satisfaction of vesting conditions relating to relative total shareholder return (Relative TSR) and continued employment during a three-year performance period.

As at 31 December 2024, there are 39,535,751 options and rights over ordinary shares on issue (2023: 8,066,333 and rights), representing 13.5% (2023: 2.87%) of the Company's total share capital, granted to the employees and Directors of the Company.

The grant dates, vesting dates and exercise prices of options and rights issued vary and are as follows:

Grant date and vesting conditions	Expiry date	Instrument	No as at 31 Dec 2023	Granted	Exercised	Lapsed	No as at 31 Dec 2024	Vested as at 31 Dec 2024
1 May 23	30 Apr 28	Options	700,000	-	-	(350,000)	350,000	-
24 Jul 23	24 Jul 28	Options	5,649,967	-	-	-	5,649,967	-
3 May 24	3 May 29	Options	-	3,361,855	-	-	3,361,855	-
16 Sep 24	16 Sep 29	Options	-	16,788,699	-	-	16,788,699	-
24 Jul 23	N/A	Rights	2,017,151	-	-	-	2,017,151	-
3 May 24	N/A	Rights	-	1,814,394	-	-	1,814,394	-
3 May 24	3 Sep 24	Rights	-	465,131	(465,131)	-	-	-
3 May 24	3 Sep 25	Rights	-	465,131	-	-	465,131	-
3 May 24	3 Sep 26	Rights	-	465,131	-	-	465,131	-
16 Sep 24	N/A	Rights	-	8,623,423	-	-	8,623,423	-
<b>Totals</b>			<b>8,367,118</b>	<b>31,983,764</b>	<b>(465,131)</b>	<b>(350,000)</b>	<b>39,535,751</b>	<b>-</b>

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 32. Share based employee incentive arrangements (continued)**

No expiry date applies to the Rights other than that any Rights for which the Vesting Conditions have not been met shall be forfeited.

As at 31 December 2024, 465,131 rights had vested and exercised being tranche 1 of the Managing Director and CEO's Sign on rights (2023: nil).

The fair value of options has been measured using the Black-Scholes formula for options granted 1 May 2023 and the Monte Carlo simulation for options granted 24 July 2023, 3 May 2024 and 16 September 2024.

The inputs used in the measurement of the fair values of options at grant date and measurement date were as follows:

	Grant date 1 May 23	Grant date 24 Jul 23	Grant date 3 May 24	Grant date 16 Sep 24
FV at grant date (USD)	0.06-0.24	0.11-0.16	0.11-0.14	0.04-0.08
Share price at grant date (USD)	0.44	0.39	0.14	0.08
Exercise price (USD)	0.45	0.49	0.25	0.15
FV at grant date (AUD)	0.09-0.16	0.16-0.23	0.17-0.22	0.06-0.12
Share price at grant date (AUD)	0.29	0.26	0.22	0.12
Exercise price (AUD)	0.68	0.59	0.38	0.22
Expected volatility	60%	60%	90%	90%
Expected life	5 years	5 years	5 years	5 years
Expected dividends	0%	0%	0%	0%
Risk free interest rate	3.08%	3.86%	4.10%	3.45%

Expected volatility is measured based on peer companies and expected life is the number of days until expiry.

The fair value of the performance rights granted during the year is calculated at the date of grant using the Monte-Carlo simulation model taking into account the simulated share price and total shareholder returns of Next Science Limited and peer companies during the vesting period. These values were calculated applying the following inputs to performance rights issued:

	Performan ce rights	Performan ce rights	Performan ce rights	Sign-on rights	Sign-on rights
Grant date	24 Jul 2023	3 May 24	16 Sep 24	3 May 24	3 May 24
Fair value per performance right (USD)	\$0.29	\$0.18	\$0.10	\$0.22	\$0.22
Fair value per performance right (AUD)	A\$0.42	A\$0.27	A\$0.15	A\$0.33	A\$0.33
Number of performance rights issued (i)	2,017,151	1,814,394	8,623,423	465,131	465,131
Remaining life of the performance rights	N/A	N/A	N/A	1 year	2 years

(i) During the financial year ended 31 December 2024, 10,440,817 Performance Rights were issued under the Company's LTI Plan (2023: 2,629,928) and 1,395,393 Sign-on rights were issued of which 465,131 vested on 10 July 2024 and were equity settled in the form of fully paid ordinary shares. No rights lapsed on 31 December 2024 due to an executive's employment ending (2023: 612,777).

**Note 33. Contingent liabilities and capital commitments**

A former employee of the Company has filed a derivative lawsuit in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, without seeking leave to do so, as required under section 237. The complaint makes various allegations against alleged officers and directors of Next Science Limited and Next Science, LLC. The Company has filed a motion to dismiss the complaint on grounds including that the plaintiff lacks standing to bring his claims due to his failure to satisfy the requirements imposed upon derivative plaintiffs by Australian law. As at the date of the authorisation of the financial statements for the year ended 31 December 2024 and on legal advice received, the Directors' are of the view there is no indication of the likelihood of an adverse finding against the Company. The directors are of the opinion that the recognition criteria for a provision has not been met, with the amount not yet capable of reliable measurement.

Other than above, the Group has no other contingent liabilities as at 31 December 2024 (2023: nil).

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 33. Contingent liabilities and capital commitments (continued)**

The Group has no capital commitments as at 31 December 2024 (2023: nil).

**Note 34. Events occurring after the reporting date**

On 8 January 2025, Next Science advised that it was involved in litigation against several former employees for breach of post-employment restraints (Non-Compete Action) and that one of the former employees had filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging mismanagement and breaches of fiduciary duties. The Company's Board of Directors is concerned that the Complaint has not been brought in good faith due to the fact that the former employee has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged.

In February 2025, the Group was issued with a Warning Letter relating to the US Food and Drug Administration (FDA) inspection of the Company's Jacksonville, Florida facility during August and September 2024. Following the FDA's inspection, the FDA provided the Company with a list of observations, via a Form FDA-483. The Group implemented corrective actions addressing the FDA's observations. The Warning Letter notes the corrective actions undertaken as well as ongoing corrective actions and states that a follow-up inspection is needed to evaluate the implementation and effectiveness of the Company's corrective actions.

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event, other than those matters detailed above, of a material and unusual nature likely, in the opinion of the directors of the Company, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group, in future financial years.

**Note 35. Remuneration of auditors**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
<i>Audit and assurance related services</i>		
<i>KPMG Australia</i>		
Audit of financial statements	167,521	121,704
<i>Other services</i>		
<i>KPMG Australia</i>		
Taxation services	107,920	25,086
Other services	29,301	24,875
<b>Total other services</b>	<u>137,221</u>	<u>49,961</u>
<b>Total auditor's remuneration</b>	<u><u>304,742</u></u>	<u><u>171,665</u></u>

**Note 36. Earnings per share**

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Loss after income tax	<u>(10,586,018)</u>	<u>(16,270,814)</u>
	<b>Number</b>	<b>Number</b>
Weighted average number of shares	291,896,447	234,094,658

**Note 36. Earnings per share (continued)**

	Cents	Cents
Basic earnings per share	(3.63)	(6.95)
Diluted earnings per share	(3.63)	(6.95)

**Note 37. Financial risk management**

**(a) Overview**

The Group's activities expose it to various financial risks including: credit risk, liquidity risk and market risk.

This note presents information about the Group's exposure to each of these risks, its objectives, policies and processes for measuring and managing risk.

**(b) Risk management framework**

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework with assistance from the Audit and Risk Committee (as detailed below). The Group's risk management framework has been established to identify and analyse the material risks faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to the risk appetite set by the Board. The Group's risk management framework is reviewed at least annually by the Audit and Risk Committee and the consideration of changes in the Group's risk profile and mitigating actions and controls is a standing item at Audit and Risk Committee meetings.

*Audit and Risk Committee*

The Audit and Risk Committee responsibilities in relation to risk management are to:

- (a) oversee the establishment, and maintenance by management, of processes to ensure that there is an adequate and effective system to identify and manage material business risks;
- (b) monitor the Group's Risk Register to confirm that key risks have been identified and adequate controls are in place to mitigate risks so far as reasonably practicable;
- (c) receive reports from management on new and emerging sources of risk and the proposed risk controls to mitigate those risks;
- (d) receive reports from management and the external auditor on any material incident involving fraud or a breakdown of the Group's risk controls and the lessons learned;
- (e) review, at least annually, the Group's risk management framework to confirm that it continues to be sound and that the Group is operating with due regard to the risk appetite set by the Board;
- (f) monitor the need for, and if considered necessary, require, an internal or external audit of critical areas of risk;
- (g) oversee the establishment of procedures for the receipt, handling and investigation of whistleblower disclosures;
- (h) oversee the establishment of, and monitor, assurance mechanisms for monitoring:
  - the Group's culture and compliance with the Group's Values; and
  - compliance with the Group's corporate governance policies and procedures, contractual obligations and the laws applicable to the Group and its operations;
- (i) oversee the Group's annual insurance program, having regard to the Group's business and the insurable risks within its business;
- (j) assess the adequacy of controls, including disaster recovery and business continuity plans, for preserving and re-establishing financial and operational information in the event of a disaster; and

**Note 37. Financial risk management (continued)**

- (k) review and make recommendations to the Board in relation to public disclosures made by the Group regarding material business risks.

The Board considers the Group's risk management framework to be appropriate for the size and level of operations of the Group.

**(c) Credit risk**

*Cash and cash equivalents*

The Group held cash and cash equivalents of USD \$1,673,917 and USD \$nil in term deposits at 31 December 2024 (2023: USD \$9,238,697 in cash and USD \$37,823 in term deposits). The cash and cash equivalents are held with credit worthy bank and financial counterparties. The expected credit loss of each of these banks and counterparties are considered to be extremely low; accordingly any expected credit losses are deemed to be insignificant.

*Trade receivables and contract assets*

Credit risk on trade receivables is the risk of financial loss if a customer fails to meet its contractual obligations.

The carrying amounts of financial assets represents the maximum credit exposure.

Maximum exposure to credit risk for trade receivables by type of counterparty was as follows:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
Distribution & Licensing Partners	492,071	918,484
Hospitals & Surgery Centres	1,619,147	787,772
Durable Medical Equipment Customers	1,203,610	1,754,447
	<u>3,314,828</u>	<u>3,460,703</u>

As at 31 December 2024, Zimmer Surgical Inc (worldwide) accounted for over 13% of the trade receivables (2023: Zimmer Surgical Inc accounted for over 23% of the trade receivables).

*(i) Risk management*

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate. Details of concentration of revenue are included in note 6.

The Audit and Risk Committee has established a credit policy under which each new customer is analysed individually for creditworthiness before the Group's standard payment and delivery terms and conditions are offered. The Group's review of new customers includes customer due diligence and credit agency information (Dun & Bradstreet Corporation), if available. Sale limits are established for each customer and reviewed periodically. Any sales exceeding those limits require approval according to an approval matrix.

The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements.

In monitoring customer credit risk, customers are grouped according to their credit characteristics, including whether they are an individual hospital or surgery centre or whether they are a distribution partner with which Next Science has a licensing or distribution agreement. Further consideration is given to their geographic location and trading history with the Group and existence of any previous financial difficulties.

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 37. Financial risk management (continued)**

*(ii) Impaired trade receivables*

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indications of this include significant financial difficulties of the debtor, the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for an extensive period of time.

Impairment losses are recognised in the profit or loss statement within selling and distribution expenses. Subsequent recoveries of amounts previously written off are credited against selling and general expenses.

As at 31 December 2024, trade receivables with a nominal value of \$Nil (2023: Nil) were considered impaired and fully provided for.

*(iii) Past due not impaired*

As at 31 December 2024, trade receivables of \$107,859 (2023: \$51,577) were past due but not impaired. These relate to customers for whom there is no recent history of default.

The aging analysis of trade receivables is as follows:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	<b>\$</b>	<b>\$</b>
0 - 30 days	1,460,774	2,175,204
31 - 60 days	1,468,000	327,215
61 - 90 days	284,725	962,119
91 - 120 days	101,328	3,835
More than 120 days	-	-
<b>Total</b>	<b><u>3,314,827</u></b>	<b><u>3,468,373</u></b>

**(d) Liquidity risk**

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. The Group manages liquidity risk by monitoring net cash balances, actual and forecast operating cash flows.

*Exposure to liquidity risk*

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted and include estimated interest payments and exclude the impact of netting agreements.

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 37. Financial risk management (continued)**

	Less than 6 months \$	6-12 months \$	Between 1 and 5 years \$	Total contracted amounts \$
<b>As 31 December 2024</b>				
Trade and other payables	2,659,324	-	-	2,659,324
Lease liabilities	132,551	135,202	463,258	731,011
<b>Total</b>	<u>2,791,875</u>	<u>135,202</u>	<u>463,258</u>	<u>3,390,335</u>
<b>As 31 December 2023</b>				
Trade and other payables	3,207,182	-	-	3,207,182
Lease liabilities	128,709	131,270	755,311	1,015,290
<b>Total</b>	<u>3,335,891</u>	<u>131,270</u>	<u>755,311</u>	<u>4,222,472</u>

The cash flows in the maturity analysis are not expected to occur significantly earlier or be for a significantly different amount than contractually disclosed above.

**(e) Market risk**

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates, will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

*Interest rate risk*

The Group is not exposed to any significant interest rate risk. There is minimal exposure to the impact of adverse changes in benchmark interest rates. The Group is exposed to variable interest rate risks at the reporting date on cash and short-term deposits. A reasonably possible change of 100 basis points in interest rates at the reporting date would have increased or decreased profit after tax by \$3,309 (2023: \$87,854). This analysis assumes that all other variables, in particular foreign currency rates, remain constant.

*Currency risk*

Currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The source and nature of this risk arise from operations and translation risks. The Group's reporting currency is United States Dollars ("USD"). However, the international operations give rise to an exposure to changes in foreign exchange rates as amounts of expenditure are from Australia and denominated in currencies other than USD.

The carrying amounts of the Group's foreign currency denominated financial assets (trade and other receivables including accrued income) and financial liabilities (trade and other payables) at the reporting date were as follows:

	<b>Consolidated</b>	
	<b>2024</b>	<b>2023</b>
	\$	\$
AUD financial assets converted to USD	1,272,599	9,140,418
AUD financial liabilities converted to USD	<u>(390,519)</u>	<u>(389,619)</u>
<b>Net exposure in statement of financial position</b>	<u>882,080</u>	<u>8,750,799</u>

A reasonably possible strengthening or (weakening) of the United States Dollar against all other currencies at 31 December 2024 would have affected the measurement of financial instruments denominated in a foreign currency and affected profit or loss and equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

**Next Science Limited**  
**Notes to the consolidated financial statements**  
**31 December 2024**

**Note 37. Financial risk management (continued)**

	<b>% Change \$</b>	<b>Profit before tax strengthen \$</b>	<b>Profit before tax weaken \$</b>	<b>Equity strengthen \$</b>	<b>Equity weaken \$</b>
<b>2024</b>					
Australian Dollars	10%	<u>88,208</u>	<u>(88,208)</u>	<u>88,208</u>	<u>(88,208)</u>
<b>2023</b>					
Australian Dollars	10%	<u>875,080</u>	<u>(875,080)</u>	<u>875,080</u>	<u>(875,080)</u>

The percentage change is the expected overall volatility of the significant currencies, which is based on management's assessment of reasonable possible fluctuations taking into consideration movements over the last 12 months and the spot rate at each reporting date.

For personal use only



**Next Science Limited**  
**Consolidated entity disclosure statement**  
**As at 31 December 2024**

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest %	Tax residency
Next Science Ltd Next Science Technologies Pty Ltd	Body corporate	Australia		Australia
Next Science IP Holdings Pty Ltd	Body corporate	Australia	100.00%	Australia
Microbial Defense Systems Holdings Inc	Body corporate	United States	100.00%	United States
Next Science Manufacturing, LLC	Body corporate	United States	100.00%	United States
Next Science, LLC	Body corporate	United States	100.00%	United States
Next Science Health Care, LLC	Body corporate	United States	100.00%	United States

*Key assumptions and judgements*

Determination of Tax Residency Section 295 (3A) of the Corporation Acts 2001 requires that the tax residency of each entity which is included in the Consolidated Entity Disclosure Statement (CEDs) be disclosed. In the context of an entity which was an Australian resident, "Australian resident" has the meaning provided in the Income Tax Assessment Act 1997. The determination of tax residency involves judgment as the determination of tax residency is highly fact dependent and there are currently several different interpretations that could be adopted, and which could give rise to a different conclusion on residency. In determining tax residency, the consolidated entity has applied the following interpretations:

**Australian tax residency:** The consolidated entity has applied current legislation and judicial precedent, including having regard to the Commissioner of Taxation's public guidance in Tax Ruling TR 2018/5.

**Foreign tax residency:** The consolidated entity has applied current legislation and where available judicial precedent in the determination of foreign tax residency. Where necessary, the consolidated entity has used independent tax advisers in foreign jurisdictions to assist in its determination of tax residency to ensure applicable foreign tax legislation has been complied with.

For personal use only

**Next Science Limited  
Directors' declaration  
31 December 2024**

In the opinion of the Directors of Next Science Limited (the "Company"):

- a. The consolidated financial statements and notes that are set out on pages 23 to 61 and the Remuneration Report on pages 10 to 21 in the Directors' Report, are in accordance with the Corporations Act 2001, including:
    - (i) giving a true and fair view of the financial position of the Group as at 31 December 2024 and of its performance for the financial year ended on that date; and
    - (ii) complying with Australian Accounting Standards and the Corporations Regulations 2001; and
  - b. there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.
2. The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the chief executive officer and chief financial officer for the financial year ended 31 December 2024.
  3. The Directors draw attention to Note 2 to the consolidated financial statements, which includes a statement of compliance with International Financial Reporting Standards.
  4. The information disclosed in the attached consolidated entity disclosure statement is true and correct.

Signed in accordance with a resolution of Directors



---

Aileen Stockburger  
Chair

28 February 2025

For personal use only



# Independent Auditor's Report

To the shareholders of Next Science Limited

## Report on the audit of the Financial Report

### Opinion

We have audited the **Financial Report** of Next Science Limited (the Company).

In our opinion, the accompanying Financial Report of the Company gives a true and fair view, including of the **Group's** financial position as at 31 December 2024 and of its financial performance for the year then ended, in accordance with the *Corporations Act 2001*, in compliance with *Australian Accounting Standards* and the *Corporations Regulations 2001*.

The **Financial Report** comprises:

- Consolidated statement of financial position as at 31 December 2024
- Consolidated statement of profit or loss and other comprehensive income, Consolidated statement of changes in equity, and Consolidated statement of cash flows for the year then ended
- Consolidated entity disclosure statement and accompanying basis of preparation as at 31 December 2024
- Notes, including material accounting policies
- Directors' Declaration.

The **Group** consists of the Company and the entities it controlled at the year end or from time to time during the financial year.

### Basis for opinion

We conducted our audit in accordance with *Australian Auditing Standards*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report.

We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the Financial Report in Australia. We have fulfilled our other ethical responsibilities in accordance with these requirements.

## Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of most significance in our audit of the Financial Report of the current period.

This matter was addressed in the context of our audit of the Financial Report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.

### Revenue Recognition – USD\$ 22,816,266

Refer to Note 5 to the Financial Report

#### The key audit matter

Revenue recognition is a key audit matter due to the significant audit effort required by us to test the Group's revenue, given:

- the significance of revenue to the financial statements;
- the high degree of estimation required to determine the consideration receivable for Durable Medical Equipment (DME) product sales;
- each customer contract including varying stipulations such as product sales, advance deposits, true-up payments, and minimum orders. These variations necessitate additional effort from the audit team to evaluate the timing and measurement of revenue recognised by the Group, as well as the associated contract liabilities;
- the Group having manual processes and controls which may increase the risk of error in recognition of revenue at the end of the reporting period due to differing terms of trade and differing delivery terms of customer contracts.

#### How the matter was addressed in our audit

Our procedures included:

- We evaluated the appropriateness of the Group's revenue recognition policies against AASB 15 *Revenue from Contracts with Customers* and our understanding of the business and industry practice. Additionally, we examined new and modified contracts to assess the Group's revenue recognition policies.
- We assessed the Group's recognition and estimation of revenue receivable for a sample of DME products through:
  - Examination of the underlying arrangements;
  - Evaluating the key assumption in the estimate, being expected receipts as a percentage of amounts billed, by 1) comparing the percentage of receipts received to that previously recognised as receivables, comparing this historical percentage used to the percentage applied by the Group in the current year estimate, and assessing circumstances at the end of the current year, using our industry knowledge, and 2) on a sample basis, comparing actual receipts after year-end to those estimated.
- For a sample of transactions across customer contracts, we tested revenue recognition and measurement for the various stipulations, including product sales, advance deposits, true-up payments, and minimum orders, by:

For personal use only

	<ul style="list-style-type: none"> <li>○ Checking the contractual stipulations of each customer agreement against the Group’s policy for timing and measurement of revenue recognition;</li> <li>○ Evaluating the amount, nature, and timing of revenue recognition by:             <ul style="list-style-type: none"> <li>- Checking the recognition for contractual stipulations in customer agreements to related documents such as freight records, sales invoices, and bank statements;</li> <li>- Assessing the revenue recognition for variable consideration, specifically true-up payments and minimum orders, by identifying relevant clauses in underlying contracts, comparing actual sales data to thresholds, and checking to underlying documents;</li> </ul> </li> <li>○ Recalculated deferred revenue based on the remaining life of the contract, checking accuracy by inspecting the underlying customer contracts.</li> </ul> <ul style="list-style-type: none"> <li>● For a sample of revenue transactions across differing terms of trade and typical delivery periods before and after the reporting year end, we performed specific cut-off tests for two weeks around period end. We checked the recorded revenue against customer contracts, sales invoices, and freight documents to address increased risks in timing of recognition.</li> <li>● Assessed the disclosures in the financial report using our understanding obtained from our testing and against the requirements of the accounting standards.</li> </ul>
--	--

## Other Information

Other Information is financial and non-financial information in Next Science Limited's annual report which is provided in addition to the Financial Report and the Auditor's Report. The Directors are responsible for the Other Information.

The Other Information we obtained prior to the date of this Auditor's Report was the Directors' Report, Remuneration Report and Corporate Directory. The Our Purpose Page, Chairman's Letter, Managing Director's Report and Investor Information are expected to be made available to us after the date of the Auditor's Report.

Our opinion on the Financial Report does not cover the Other Information and, accordingly, we do not and will not express an audit opinion or any form of assurance conclusion thereon, with the exception of the Remuneration Report and our related assurance opinion.

In connection with our audit of the Financial Report, our responsibility is to read the Other Information. In doing so, we consider whether the Other Information is materially inconsistent with the Financial Report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We are required to report if we conclude that there is a material misstatement of this Other Information, and based on the work we have performed on the Other Information that we obtained prior to the date of this Auditor's Report we have nothing to report.

## Responsibilities of the Directors for the Financial Report

The Directors are responsible for:

- preparing the Financial Report in accordance with the *Corporations Act 2001*, including giving a true and fair view of the financial position and performance of the Group, and in compliance with *Australian Accounting Standards* and the *Corporations Regulations 2001*
- implementing necessary internal control to enable the preparation of a Financial Report in accordance with the *Corporations Act 2001*, including giving a true and fair view of the financial position and performance of the Group, and that is free from material misstatement, whether due to fraud or error
- assessing the Group and Company's ability to continue as a going concern and whether the use of the going concern basis of accounting is appropriate. This includes disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless they either intend to liquidate the Group and Company or to cease operations, or have no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the Financial Report

Our objective is:

- to obtain reasonable assurance about whether the Financial Report as a whole is free from material misstatement, whether due to fraud or error; and
- to issue an Auditor's Report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with *Australian Auditing Standards* will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error. They are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Financial Report.

A further description of our responsibilities for the audit of the Financial Report is located at the *Auditing and Assurance Standards Board* website at [https://www.auasb.gov.au/media/bwvjcgre/ar1\\_2024.pdf](https://www.auasb.gov.au/media/bwvjcgre/ar1_2024.pdf). This description forms part of our Auditor's Report.

## Report on the Remuneration Report

### Opinion

In our opinion, the Remuneration Report of Next Science Limited for the year ended 31 December 2024, complies with *Section 300A* of the *Corporations Act 2001*.

### Directors' responsibilities

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with *Section 300A* of the *Corporations Act 2001*.

### Our responsibilities

We have audited the Remuneration Report included in pages 10 to 21 of the Directors' report for the year ended 31 December 2024.

Our responsibility is to express an opinion as to whether the Remuneration Report complies in all material respects with *Section 300A* of the *Corporations Act 2001*, based on our audit conducted in accordance with *Australian Auditing Standards*.



KPMG



Kevin Leighton

Partner

Sydney

28 February 2025

**Next Science Limited  
Corporate Directory  
31 December 2024**

**Directors**

Independent Non-Executive Chairman:

Aileen Stockburger

Managing Director:

Harry Thomas Hall, IV

Non-Executive Directors:

Grant Hummel

Katherine Ostin

Company Secretary

Gillian Nairn

Registered office

HWL Ebsworth  
Level 14, Australia Square  
264-278 George Street  
Sydney NSW 2000

Share register

Link Market Services Limited  
Level 12, 680 George Street  
Sydney NSW 2000

Auditor

KPMG Australia  
300 Barangaroo Avenue  
Sydney  
NSW 2000

Solicitors

HWL Ebsworth Lawyers  
Level 14, Australia Square  
264-278 George Street  
Sydney NSW 2000

Stock exchange listing

Next Science Limited shares are listed on the Australian Securities Exchange (ASX code: NXS)

Website

[www.nextscience.com](http://www.nextscience.com)

Corporate governance statement

<https://www.nextscience.com/corp-governance/>

For personal use only